Prof. Dr. Claus Rödel

Rödel C, Fietkau R, Grabenbauer GG, Keilholz L, Martus P, Kessler R, Sauer R. Akuttoxizität der simultanen Radiochemotherapie des Rektumkarzinoms. Strahlenther Onkol 1997;173:414-20.

Wendt TH, Grabenbauer GG, Rödel C, Thiel HJ, Aydin H, Rohloff R, Wustrow TP, Iro H, Popella C, Schalhorn A. Simultaneous radio-chemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998;16:1318-24.

Grüner A, Grabenbauer GG, Rödel C, Weidenbecher M, Martus P, Iro H, Sauer R. Nasopharynxkarzinom: Nur Bestrahlung oder simultane Radiochemotherapie? Strahlenther Onkol 1999;175:591-96.

Rödel C, Grabenbauer GG, Matzel KL, Schick C, Fietkau R, Papadopoulos T, Martus P, Hohenberger W, Sauer R. Extensive surgery after high-dose preoperative chemoradiotherapy for locally advanced recurrent rectal cancer. Dis Colon Rectum 2000;43:312-19.

Rödel C, Grabenbauer GG, Rödel F, Birkenhake S, Kühn R, Martus P, Fürsich D, Papadoupolos T, Dunst J, Sauer R. Apoptosis, p53, Ki-67 and bcl-2: possible predictors for successful bladder preservation by transurethral resection and radiochemotherapy. Int J Radiat Oncol Biol Phys 2000;46:1213-21.

Grabenbauer GG, Schuchardt U, Buchfelder M, Rödel C, Gusek G, Marx M, Doerr HG, Fahlbusch R, Huk WJ, Wenzel D, Sauer R. Radiation therapy of optico-hypothalamic gliomas (OHG) – radiographic response, vision and late toxicity. Radiother Oncol 2000,54:239-45.

Rödel C, Grabenbauer GG, Schick C, Papadopoulos T, Hohenberger W, Sauer R. Preoperative radiation with concurrent 5-fluorouracil for locally advanced primary T4-rectal cancer. Strahlenther Onkol 2000,176:161-67.

Grabenbauer GG, Mühlfriedel C, Rödel F, Niedobitek G, Hornung J, Rödel C, Martus P, Iro H, Kirchner T, Steininger H, Sauer R, Weidenbecher M, Distel L. Squamous cell carcinoma of the oropharynx: Ki-67 and p53 can identify patients at risk for local recurrence after surgery and postoperative radiotherapy. Int J Radiat Oncol Biol Phys 2000;48:1041-50.

Grabenbauer GG, Rödel C, Paulus W, Gansland O, Schuchard U, Buchfelder M, Schrell U, Huk W, Sauer R. Supratentorial low-grade glioma: results and prognostic factors following postoperative radiotherapy. Strahlenther Onkol 2000;176:259-264.

Rödel C, Dunst J, Grabenbauer GG, Kühn R, Papadopoulos T, Schrott KM, Sauer R: Radiotherapy is an effective treatment for high-risk T1-bladder cancer. Strahlenther Onkol 2001;177:82-88.

Sauer R, Fietkau R, Wittekind C, Martus P, Rödel C, Hohenberger W, Jatzko G, Sabitzer H, Karstens JH, Becker H, Hess C, Raab R. Adjuvant versus neoadjuvant radiochemotherapy for locally advanced rectal cancer: a progress report of a phase-III randomized trial. Strahlenther Onkol 2001,177: 173-81.

Grabenbauer GG, Rödel C, Brunner T, Schulze-Mosgau S, Strnad V, Müller RG, Iro H, Sauer R. Interstitial brachytherapy with Ir-192 low-dos rate in the treatment of primary and recurrent cancer of the oral cavity and oropharynx. Strahlenther Onkol 2001:177:338-44.

Rödel C, Grabenbauer GG, Kühn R, Dunst J, Papadopoulos T, Schrott KM, Sauer R. Invasive bladder cancer: organ preservation by radiochemotherapy. Front Radiat Ther Oncol, 2002;36:118-130.

Rödel C, Grabenbauer GG, Papadoupolos T, Bigalke M, Günther K, Schick C, Sauer R, Rödel F. Apoptosis as cellular predictor of histopathological response to neoadjuvant radiochemo- therapy in patients with rectal cancer. Int J Radiat Oncol Biol Phys 2002;52: 294-303.

Rödel C, Grabenbauer GG, Kühn R, Dunst J, Zörcher T, Papadopoulos T, Schrott KM, Sauer R. Organ preservation in bladder cancer: Initial results of an intensified protocol of transurethral resection, radiation therapy and concurrent cisplatin and 5-fluorouracil. Int J Radiat Oncol Biol Phys 2002;52:1303-09.

Rödel F, Hoffmann J, Grabenbauer GG, Papadopoulos T, Weiß C, Günther C, Schick C, Sauer R, Rödel C. High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection. Strahlenther Onkol, 2002;78:426-35.

Rödel C, Grabenbauer GG, Kühn R, Papadopoulos T, Dunst J, Meyer M, Schrott KM, Sauer R. Combined modality treatment and selective organ preservation in invasive bladder cancer: Long-term results. J Clin Oncol 2002;20:3061-71.

Grabenbauer GG, Rödel C, Brunner Th, Hornung J, Kittel K, Schulze-Mosgau S, Steinhart H, Iro H, Sauer R. Neck dissection following radiochemotherapy of advanced head and neck cancer – for selected cases only? Radiother Oncol, 2003;66:57-63.

Fuchs S, Rödel C, Brunner T, Iro H, Niedeobitek G, Sauer R, Grabenbauer GG. Patterns of failure following radiation with or without chemotherapy in patients with nasopharyngeal carcinoma. Onkologie 2003;26:12-18.

Rödel C, Haas J, Groth A, Grabenbauer GG, Sauer R, Rödel F. Spontaneous and radiation induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor. Int J Radiat Oncol Biol Phys 2003;55:1341-47.

Grabenbauer GG, Suckorade O, Niedobitek G, Rödel F, Iro H, Rödel C, Schulze-Mosgau S, Distel L. Imbalance between proliferation and apoptosis may be responsible for treatment failure after postoperative radiotherapy in squamous cell carcinoma of the oropharynx. Oral Oncology 2003;39:459-69.

Humeny A, Rödel F, Rödel C, Sauer R, Füzesi L, Becker CM, Efferth T. MDR 1 single nucleotide polymorphism C3435T in normal colorectal tissue and colorectal carcinomas detected by MALDI-TOF mass spectrometry. Anticancer Res 2003;23(3B):2735-40.

Rödel C, Grabenbauer GG, Papadopoulos T, Hohenberger W, Schmoll HJ, Sauer R. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 2003;21:3098-104.

Günther K, Dimmler A, Rödel F, Reulbach U, Merkel S, Bittorf B, Matzel K, Papadopoulos T, Hohenberger W, Sauer R, Rödel C. P27 expression does not predict histopathological response to radiochemotherapy in rectal cancer. J Surg Res 2003;113:179-88.

Göhl J, Merkel S, Rödel C, Hohenberger W: Can neoadjuvant radiochemo-therapy improve the results of multivisceral resections in advanced rectal carcinoma (cT4a). Int J Colorectal Dis 2003;5:436-41.

Sauer R, Fietkau R, Wittekind C, Rödel C, Martus P, Hohenberger W, Tschmelitsch J, Sabitzer H, Karstens JH, Becker H, Hess C, Raab R. Adjuvant versus neoadjuvant radiochemotherapy for locally advanced rectal cancer: the German trail CAO/ARO/AIO-94. Int J Colorectal Dis 2003;5:406-15.

Ott OJ, Rödel C, Gramatzki M, Niedobitek G, Sauer R, Grabenbauer GG. Radiotherapy for stage I-III nodal low-grade Non-Hodgkin’s Lymhoma. Strahlenther Onkol 2003;179:694-701.

Rödel F, Hantschel M, Hildebrandt G, Schultze-Mosgau S, Rödel C, Herrmann M, Sauer R, Voll RE. Dose-dependent biphasic induction and transcriptional activity of nuclear factor kappa B (NF-kB) in EA.hy.926 endothelial cells after low-dose X-irradiation. Int J Radiat Biol 2004;80:115-23.

Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess C, Karstens JH, Liersch T, Schmidberger H, Raab R, for the German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer. N Engl J Med 2004;351:1731-40.

Rödel F, Hoffmann J, Distel L, Herrmann M, Noistering T, Papadopoulos T, Sauer R, Rödel C. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 2005;65:4881-87.

Weiss C, Rödel F, Wolf I, Papadoupoulos T, Schrott KM, Sauer R, Rödel C. Combined modality treatment and organ preservation in bladder cancer: Do molecular marker predict outcome? Strahlenther Onkol 2005;181:213-22.

Akcetin Z, Todorov J, Tuzel E, Engehausen DG, Krause FS, Sauer R, Schrott KM, Rödel C. Radiochemotherapy after transurethral resection is an effective treatment method in T1G3 bladder cancer. Anticancer Res 2005;25:1623-28.

Rödel C, Martus P, Papadopoulos T, Füzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R, Wittekind C. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005;23: 8688-96.

Weiss C, Wolze C, Engehausen DG, Ott O, Ott JO, Krause FS, Schrott KM, Dunst J, Sauer R, Rödel C. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: An alternative to intravesical therapy or early cystectomy. J Clin Oncol 2006;24:2318-24.

Baierlein S, Distel L, Sieber R, Weiss C, Rödel C, Sauer R, Rödel F. Combined effect of tumor necrosis factor-alpha and ionizing radiation on the induction of apoptosis in B5637 bladder carcinoma cells. Strahlenther Onkol 2006;182:467-72.

Knauer SK, Krämer O, Knösel T, Engels K, Rödel F, Kovacs AF, Dietmaier W, Klein-Hitpass L, Habtemichael N, Schweitzer A, Brieger J, Rödel C, Mann W, Petersen I, Heinzel T, Stauber RH. Nuclear export is essential for the tumor promoting activity of survivin. FASEB J 2007;21:207-16.

Rödel C, Liersch T, Hermann RM, Arnold D, Reese T, Hipp M, Fürst A, Schwella N, Bieker M, Hellmich G, Ewald H, Haier J, Lordick F, Flentje M, Sülberg H, Hohenberger W, Sauer R. Multicenter phase II trial of chemoradiotherapy with oxaliplatin for rectal cancer. J Clin Oncol 2007;25:110-17.

Fietkau R, Rödel C, Hohenberger W, Raab R, Hess C, Liersch T, Becker H, Wittekind C, Hutter M, Hager E, Karstens J, Ewald H, Schorcht J, Jagoditsch M, Martus P, Sauer R. Rectal cancer delivery of radiotherapy in adequate time and with adequate dose is influenced by treatment center, treatment schedule, and gender and is prognostic parameter for local control: results of study CAO/ARO/AIO-94. Int J Radiat Oncol Biol Phys 2007;67:1008-19.

Weiss C, Engehausen D, Krause FS, Papadoupolos T, Dunst J, Sauer R, Rödel C. Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer. Int J Radiat Oncol Biol Phys 2007, 68:1072-80.

Weiss C, Rödel F, Ott O, Engehausen D, Papadoupolos T, Sauer R, Rödel C. Pretreatment proliferation and local control in bladder cancer after conventional radiotherapy with or without concurrent chemotherapy. Strahlenther Onkol 2007,183:551-55.

Rödel C, Arnold D, Hipp M, Liersch T, Dellas K, Iesalnieks I, Hermann RM, Lordick M, Hinke A, Hohenberger W, Sauer R. Phase I/II trial of cetuximab, capecitabine, oxaliplatin, and radiation therapy as preoperative treatment in rectal cancer. Int J Radiat Oncol Biol Phys 2008;70:1081-86.

Weiss C, Wittlinger M, Engehausen D, Krause F, Ott O, Dunst J, Sauer R, Rödel C. Management of superficial recurrences in an irradiated bladder after combined modality organ preserving therapy. Int J Radiat Oncol Biol Phys 2008, 70:1502-506.

Capirci C, Valentini V, Cionini L, De Paoli A, Rödel C, Glynne-Jones R, Coco C, Romano M, Mantello G, Pmalazzi S, Friso ML, Genovesi D, Vidali C, Gambacorta MA, Buffoli A, Lapattelli M, Favretto MS, La Torre G. Prognostic value of pathological complete response (ypCR) after preoperative chemoradiotherapy in locally advanced rectal cancer: long term analysis on 566 ypCR patients. Int J Radiat Oncol Biol Phys 2008; 72:99-107.

Dunst J, Debus J, Rudat V, Wulf J, Budach W, Hoelscher T, Reese T, Mose S, Rödel C, Zuehlke H, Hinke A. Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer. Strahlenther Onkol 2008;184:450-56.

Croner R, Reingruber B, Förtsch T, Brückl W, Rödel F, Rödel C, Klein-Hitpass L, Papadopoulos T, Brabletz T, Kirchner T, Sachs M, Behrens J, Stürzl M, Hohenberger W, Lausen B. Molecular signature for lymph node metastases in colorectal carcinomas. Ann Surg 2008;247:803-10.

Ramm U, Licher J, Moog J, Scherf C, Kara E, Böttcher HD, Rödel C, Mose S. In vivo dosimetry with semiconducting diodes for dose verification in total body irradiation: a 10-year experience. Strahlenther Onkol 2008,184:376-80.

Rödel F, Frey B, Leitmann W, Capalbo G, Weiss C, Rödel C. Survivin antisense oligonucleotides effectively radiosensitize colorectal cancer cells both in vitro and in mice. Int J Radiat Oncol Biol Phys 2008;71:247-55.

Frauenholz I, Eberlein K, Schopohl B, Böttcher HD, Rödel C. Selenium levels during the course of radiotherapy: No influence of irradiation on blood selenium concentrations. Strahlenther Onkol 2008;184:411-15.

Lang-Welzenbach M, Rödel C, Vollmann J. Patientenverfügungen in der Radioonkologie: Einstellungen von Patienten, Ärzten und Pflegepersonal. Ethik Med 2008;20:300-12.

Kalata P, Martus P, Zettl H, Rödel C, Hohenberger W, Raab R, Becker H, Liersch T, Wittekind C, Sauer R, Fietkau R. Differences between clinical trial participants and patients in a population-based registry: The German rectal cancer study vs. the Rostock Cancer Registry. Dis Colon Rectum 2009; 52:425-37.

Rödel F, Capalbo G, Rödel C, Weiss C. Caveolin-1 as a predictive marker for local control after preoperative chemoradiation therapy in rectal cancer. Int J Radiat Oncol Biol Phys 2009;73:846-52.

Weiss C, von Römer F, Capalbo G, Ott O, Wittlinger M, Krause S, Sauer R, Rödel C, Rödel F. Survivin expression as a predictive marker for local control in patients with high-rsik T1 bladder cancer treated with transurethral resection and radiochemotherapy. Int J Radiat Oncol Biol Phys 2009;74:1455-60.

Bölling T, Seegenschmiedt H, Semrau R, Rödel C. Training in radiation oncology in Germany – current status and necessary developments. Strahlenther Onkol 2009,185:275-81.

Den Dulk M, Putter H, Collette L, Marijnen C, Folkesson J, Bosset JF, Rödel C, Buijko K, Pahlmann L, van der Velde C. The abdominoperineal resection itself is associated with an adverse outcome: the European experience based on a pooled analysis of five European randomized clinical trials on rectal cancer. Eur J Cancer 2009;45:1175-83.

Den Dulk M, Marijnen CA, Collette L, Putter H, Pahlmann L, Folkesson J, Bosset JF, Rödel C, Buijko K, van der Velde CJ. Multicentre analysis of oncological and survival outcomes following anastomotic leakage after rectal cancer surgery. Br J Surg 2009;96:1066-75.

Scherf C, Peter C, Moog J, Licher J, Kara E, Zink K, Rödel C, Ramm U. Silicon diodes as an alternative for diamond detectors for depth dose curves and profile measurements of photonhs and electron radiation. Strahlenther Onkol 2009;185:530-36.

Eberlein K, Fraunholz I, Rödel C, Jühling-Polith L. Changes in blood test after irradiation with high doses for inactivation of Lassa virus. Eur J Clin Microbiol Infect Dis 2009; 28:1155-57.

Rödel F, Keilholz L, Herrmann M, Frey B, Voll R, Gaipl U, Rödel C. Activator protein 1 (AP-1) shows a biphasic induction and transcriptional activity after low dose X-irradiation in EA.hy.292 endothelial cells. Autoimmunity 2009;42:343-45.

Wittlinger M, Rödel C, Weiss C, Krause S, Kühn R, Fietkau R, Sauer R, Ott O. Quadrimodal treatment of high-risk T1 and T2 bladder cancer: Transurethral tumor resection followed by concurrent radiochemotherapy and regional hyperthermia. Radiother Oncol 2009; 93:358-63.

Balermpas P, Hambek M, Seitz O, Rödel C, Weiss C. Combined cetuximab and re-irradiation for recurrent inoperable squamous cell carcinoma of head and neck. Strahlenther Onkol 2009;185:775-81.

Fraunholz I, Weiss C, Eberlein K, Haberl A, Rödel C. Concurrent chemoradiation therapy with 5-FU and mitomycin C for invasive anal carcinoma in HIV-positive patients receiving highly active antiretroviral therapy. Int J Radiat Oncol Biol Phys 2010;76:1425-32.

Weiss C, Fietkau R, Sauer R, Arnold D, Hipp, Dellas, Liersch T, Hinke A, Rödel C. Preoperative radiotherapy with capecitabine and oxaliplatin with or without cetuximab: A pooled analysis of three prospective phase I-II trials. Int J Radiat Oncol Biol Phys 2010;78:472-78.

Heyd R, Dorn AP, Herkströter M, Rödel C, Müller-Schimpfle M, Fraunholz I. Radiation therapy for early stages of Morbus Ledderhose. Strahlenther Onkol 2010;186:24-9

Capalbo G, Dittmann K, Weiss C, Hausmann E, Rödel C, Rödel F. Radiation-induced survivin nuclear import is linked to DNA damage repair. Int J Radiat Oncol Biol Phys 2010;77:226-34.

Rödel F, Keppner S, Capalbo G, Bashary R, Kaufmann M, Rödel C, Strebhard K, Spänkuch B. Polo-like kinase 1 as predictive factor and therapeutic target for radiotherapy in rectal cancer. Am J Pathol 2010;177:918-29.

Rödel F, Frey B, Capalbo G, Gaipl U, Keilholz L, Voll R, Hildebrandt G, Rödel C. Biphasic induction of X-linked Inhibitor of Apoptosis in EA.hy.926 endothelial cells is linked to NF-kappaB activation and mediates the anti-inflammatory properties of low-dose ionizing radiation. Radiother Oncol 2010;97:346-51.

Gerstein J, Franz K, Steinbach J, Seifert V, Fraunholz I, Weiss C, Rödel C. Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma. Radiother Oncol 2010;97:382-86.

Maas M, Nelemans PJ, Valentini V, Das P, Rödel C, Kuo LJ, Calvo FA, García-Aguilar J, Glynne-Jones R, Haustermans K, Mohiuddin M, Pucciarelli M, Small Jr W, Suárez J, Theodoropoulos G, Biondo S, Beets-Tan R, Beets GL, Long-term outcome in patients with a pathologic complete response after chemoradiation for rectal cancer: a pooled analysis of 3105 patients. Lancet Oncol 2010;11:835-44.

Fraunholz I, Rabeneck D, Gerstein J, Jäck K, Haberl A, Weiss C, Rödel C. Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for anal carcinoma: Are there differences between HIV-positive and HIV-negative patients in the era of highly active antiretroviral therapy? Radiother Oncol, 2011;98:99-104.

Krause FS, Walter B, Ott O, Häberle L, Weiss C, Rödel C, Wullich B, Sauer R. 15-Year Survival Rates of Transurethral Resection and Radiochemotherapy or Radiation in Bladder Cancer Treatment. Anticancer Res 2011;31:985-90.

Liebich J, Licher J, Scherf C, Kara E, Koch N, Rödel C, Ramm U. Simple guidance for dosimetry with an Elekta iViewGTTM EPID using commercial software modules. Strahlenther Onkol 2011;187:316-21.

Sprenger T, Rödel F, Beissbarth T, Conradi LC, Rothe H, Homayounfar K, Wolff H, Ghadimi BM, Yildirim M, Becker H, Rödel C, Liersch T. Failure of downregulation of survivin expression following neoadjuvant chemoradiation in rectal cancer is associated with distant metastases and shortened survival. Clin Cancer Res 2011;17:1623-31.

Fraunholz I, Grau K, Weiss C, Rödel C. Patient- and treatment related risk factors for nausea and emesis during concurrent chemoradiotherapy. Strahlenther Onkol 2011;187:1-6.

Grimminger PP, Danenberg P, Dellas K, Arnold D, Rödel C, Machiels JP, Haustermans K, Debucquoy A, Velenik V, Sempoux C, Bracko M, Hölscher AH, Semrau R, Yang D, Danenberg K, Lenz HJ, Vallböhmer D. Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer. Clin Cancer Res 2011;17:3469-77.

Hermanek P, Hohenberger W, Fietkau R, Rödel C. Individualized MRI-based neoadjuvant chemoradiation for middle and lower rectal carcinoma. Colorectal Dis 2011;13:39-47.

Valentini V, van Stiphout R, Lammering G, Gambacorta MA, Barba MC, Bujko K, Bebenek M, Cionini L, Sainato A, Rödel C, Sauer R, Bonnetain F, Gerard JP, Bosset JS, Collette L, Lambin P. Nomograms for predicting local recurrence, distant metastases and overall survival for locally advanced rectal cancer patients based on European randomized clinical trials. J Clin Oncol 2011;29:3163-72.

Hu-Lieskovan S, Vallbohmer D, Zhang W, Pohl A, Labonte M, Yang D, Arnold D, Debucquoy A, Dellas K, Grimminger P, Haustermans K, Hölscher A, Machiels JP, Rödel C, Sempoux C, Semrau R, Velenik V, Lenz HJ. EGF +61 A>G polymorphism predicts complete pathologic response independent of K ras status in locally advanced rectal cancer patients undergoing neoadjuvant cetuximab-based chemoradiation. Clin Cancer Res 2011;17:5161-69.

Gerstein J, Franz K, Steinbach JP, Seifert V, Rödel C, Weiss C. Radiochemotherapy with temozolomide for patients with glioblastoma: Prognostic factors and long-term outcome of unselected patients from a single institution. Strahlenther Onkol 2011;187:722-28.

Reichert S, Rödel C, Mirsch J, Harter PH, Tomicic MT, Mittelbronn M, Kaina B, Rödel F. Survivin-inhibition and DNA double-strand break repair: A molecular mechanism to overcome radioresistance in glioblastoma. Radiother Oncol 2011;101:51-58.

Balermpas P, Keller C, Hambek M, Wagenblast J, Seitz O, Rödel C, Weiss C. Re-Irradiation with cetuximab in locoregional recurrent and inoperable squamous cell carcinoma of the head and neck: Feasibility and first efficacy results. Int J Radiat Oncol Biol Phys 2012;83:e377-83.

Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, Becker H,  Raab HR,Villanueva MT, Witzigmann H, Wittekind C, Beissbarth T, Rödel C. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: Results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow up of 11 years. J Clin Oncol 2012;30:1926-33.

Reichert S, Reinboldt V, Hehlgans S, Efferth T, Rödel C, Rödel F. A radiosensitizing effect of artesunate in glioblastoma cells is associated with diminished expression of the inhibitor of apoptosis protein survivin. Radiother Oncol 2012;103:394-401.

Gaca S, Reichert S, Rödel C, Rödel F, Kreuter J. Survivin-miRNA-loaded nanoparticles as auxiliary tools for radiation therapy: Preparation, characterisation, drug release, cytotoxicity, and therapeutic effect on colorectal cancer cells. Journal of Microencapsulation 2012;29:685-94.

Wolff R, Seifert V, Mack A, Steinbach J, Rödel C, Heyd R. Gamma knife radiosurgery of recurrent atypical neurocytoma. Strahlenther Oncol 2012;188:707-11

Rödel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, Graeven U, Arnold D, Lang-Welzenbach M, Raab R, Sülberg H, Wittekind C,  Potapov S, Staib L, Hess C, Weigang-Köhler K, Grabenbauer G, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R. Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: Initial results of the German CAO/ARO/AIO-04 randomized phase 3 trial. Lancet Oncol 2012;13:679-87.

Fraunholz I, Rödel C, Distel L, Rave-Fränk M, Kohler D, Falk S, Rödel F. High survivin expression as a risk factor in patients with anal carcinoma treated with concurrent chemoradiotherapy. Radiat Oncol. 2012;7:88.

Laurberg JR, Brems-Eskildsen AS, Nordentoft I, Fristrup N, Schepeler T, Ulhøi BP, Agerbaek M, Hartmann A, Bertz S, Wittlinger M, Fietkau R, Rödel C, Borre M, Jensen JB, Orntoft T, Dyrskjøt L. Expression of TIP60 (tat-interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment-specific outcome of localised invasive bladder cancer. BJU Int 2012; 110:E1228-36.

Keck B, Ott OJ, Häberle L, Kunath F, Weiss C, Rödel C, Sauer R, Fietkau R, Wullich B, Krause FS. Female sex is an independent risk factor for reduced overall survival in bladder cancer patients treated by transurethral resection and radio- or radiochemotherapy. World J Urol 2013;31:1023-8.

Sprenger T, Conradi LC, Beissbarth T, Ermert H, Middel P, Rüschoff J, Wolff HA, Rödel C, Ghadimi BM, Becker H, Rödel F, Liersch T. Enrichment of CD133+ cells in rectal cancers treated with preoperative radiochemotherapy is an independent prognostic marker for metastasis and survival. Cancer 2013; 119:26-35.

Conradi LC, Styczen H, Sprenger T, Wolff HA, Rödel C, Nietert M, Homayounfar K, Gaedcke J, Kitz J, Talaulicar R, Becker H, Ghadimi M, Middel P, Beissbarth T, Rüschoff J, Liersch T. Frequency of HER-2 Positivity in Rectal Cancer and Prognosis. Am J Surg Pathol 2013;37:522-31

Moehler M, Gockel I, Roessler HP, Arnold D, Trarbach T, Thomaidis T, Klautke G, Rödel C, Brenner B, Lang H, Galle PR, Schimanski CC, Schmidberger H. Prospective open, multicentre phase I/II trial to assess the safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction. BMC Cancer 2013; 11;13:75.

Fokas E, Conradi L, Weiss C, Sprenger T, Middel P, Rau  T, Dellas K, Kitz J, Rödel F, Sauer R, Rüschoff J, Beissbarth T, Arnold D, Ghadimi BM, Rödel C, Liersch T. Preoperative radiochemotherapy with capecitabine/oxaliplatin and cetuximab in rectal cancer: long-term results of a prospective phase-I/II study. Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):992-99.

Gaca S, Reichert S, Multhoff G, Wacker M, Hehlgans S, Botzler C, Gehrmann M,  Rödel C, Kreuter J, Rödel F. Targeting by cmHsp70.1-antibody coaded and survivin miRNA plasmid loaded nanoparticles to radiosensitize glioblastoma cells. J Controlled Release 2013;172:201-206.

Fietkau R, Lewitzki V, Kuhnt T, Baumann M, Hess CF, Berger B, Wiegel T, Rödel C, Niewald M, Hermann RM, Lubgan D. A disease-specific enteral nutrition formula improves nutritional status and functional performance in patients with head and neck- and oesophageal cancer undergoing chemoradiotherapy – results of a randomised, controlled multicenter trial. Cancer 2013;119:3343-53.

Wolff HA, Conradi LA, Beissbarth T, Leha A, Hohnberger W, Merkel S, Fietkau R, Raab HR, Tschmelitsch J, Hess CF, Becker H, Wittekind CH, Sauer R, Rödel C, Liersch T. Gender affects acute organ toxicity during radiochemotherapy for rectal cancer: Long-term results of the German CAO/ARO/AIO-94 phase III trial. Radiother Oncol 2013;108:48-54.

Fraunholz I, Rödel F, Kohler D, Diallo-Georgiopoulou M, Distel L, Falk S, Rödel C. Epidermal growth factor receptor expression as prognostic marker in patients with anal carcinoma treated with concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 2013;86:901-7.

Dellas K, Höhler T, Reese T, Würschmidt F, Engel E, Rödel C, Wagner W, Richter M, Arnold D, Dunst J. Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer. Radiat Oncol 2013;15;8(1):90.

Balermpas P, Michel Y, Wagenblast J, Seitz O, Sipek F, Rödel F, Rödel C, Fokas E. Nuclear NF-κB expression correlates with outcome amongst patients with head and neck squamous cell carcinoma treated with primary chemoradiotherapy. Int J Radiat Oncol Biol Phys 2013;86:785-90.

Sprenger T, Rothe H, Beissbarth T, Homayounfar K, Gauss K, Kitz J, Wolff H, Ghadimi M, Rödel C, Conradi LC, Liersch T. Lymph node metastases in rectal cancer after preoperative radiochemotherapy: Impact of intramesorectal distribution and residual micrometastatic involvement. Am J Surg Pathol 2013; 37(8):1283-9

Hehlgans S, Petraki C, Reichert S, Cordes N, Rödel C, Rödel F. Double targeting of survivin and XIAP radiosensitizes 3D grown human colorectal cancer cells and decreases migration and invasion. Radiother Oncol 2013, 108:32-9.

Fraunholz IB, Haberl A, Klauke S, Gute P, Rödel CM. Long-term Effects of Chemoradiotherapy for Anal Cancer in Patients With HIV Infection: Oncological Outcomes, Immunological Status, and the Clinical Course of the HIV Disease. Dis Colon Rectum. 2014;57:423-31.

Ramm U, Köhn J, Rodriguez Dominguez R, Licher J, Koch N, Kara E, Scherf C, Rödel C, Weiß C. Feasibility study of patient positioning verification in electron beam radiotherapy with an electronic portal imaging device (EPID). Physica Medica, 2014; 30:215-220.

Blümer N, Scherf C, Köhn J, Kara E, Loutfi-Krauß B, Imhoff D, Rödel C, Ramm U, Licher J. New possibilities for volumetric-modulated arc therapy using the AgilityTM 160-leaf multileaf collimator.  Strahlenther Onkol 2014;190:1066-74.

Balermpas P, Bauer C, Fraunholz I, Ottinger A, Wagenblast J, Stöver T, Seitz O, Fokas E, Rödel C, Weiss C: Concomitant chemoradiotherapy versus induction chemotherapy followed by chemoradiotherapy as definitive, first line treatment of squamous cell carcinoma of the head and neck. A retrospective single center analysis. Strahlenther Onkol 2014 Mar;190(3):256-262.

Schulze B, Bergis D, Balermpas P, Armbruster R, Trojan J, Woeste G, Bechstein WO, Rödel C, Weiss C. Neoadjuvant chemoradiation followed by surgery versus perioperative chemotherapy followed by surgery in resectable adenocarcinomas of the esophagogastric junction – a single center retrospective analysis. Oncol Lett 2014;7:534-540.

Schulze B, Meissner M, Wolter M, Rödel C, Weiss C. Unusual acute and delayed skin reactions during and after whole-brain radiotherapy in combination with the BRAF inhibitor vemurafenib. Two case reports. Strahlenther Onkol. 2014;190:229-32.

Fokas E, Liersch T, Fietkau R, Hohenberger W, Beissbarth T, Hess C, Becker H, Ghadimi M, Mrak K, Merkel S, Raab HR, Sauer R, Wittekind C, Rödel C. Tumor Regression Grading After Preoperative Chemoradiotherapy for Locally Advanced Rectal Carcinoma Revisited: Updated Results of the CAO/ARO/AIO-94 Trial. J Clin Oncol. 2014 May 20;32(15):1554-62.

Large M, Reichert S, Hahlgans S, Fournier C, Rödel C, Rödel F. A non-linear detection of phospho-histone H2AX in EA.hy926 endothelial cells following low-dose X-irradiation is modulated by reactive oxygen species. Radiat Oncol. 2014;9(1):80.

Balermpas P, Michel Y, Wagenblast J, Seitz O, Weiss C, Rödel F, Rödel C, Fokas E. Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer. Br J Cancer. 2014;110(2):501-9. Erratum in: Br J Cancer. 2014;110(2):547.

Fraunholz IB, Haberl A, Klauke S, Gute P, Rödel CM. Long-term Effects of Chemoradiotherapy for Anal Cancer in Patients With HIV Infection: Oncological Outcomes, Immunological Status, and the Clinical Course of the HIV Disease. Dis Colon Rectum. 2014 Apr;57(4):423-31.

Lohaus F, Linge A, Tinhofer I, Budach V, Gkika E, Stuschke M, Balermpas P, Rödel C, Avlar M, Grosu AL, Abdollahi A, Debus J, Bayer C, Belka C, Pigorsch S, Combs SE, Mönnich D, Zips D, von Neubeck C, Baretton GB, Löck S, Thames HD, Krause M, Baumann M; DKTK-ROG. HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiother Oncol 2014;113:317-23.

Keck B, Wach S, Taubert H, Zeiler S, Ott OJ, Kunath F, Hartmann A, Bertz S, Weiss C, Hönscheid P, Schellenburg S, Rödel C, Baretton GB, Sauer R, Fietkau R, Wullich B, Krause FS, Datta K, Muders MH. Neuropilin-2 and Its ligand VEGF-C predict treatment response after transurethral resection and radiochemotherapy in bladder cancer patients. Int J Cancer 2015;136:443-51.

Rödel F, Wieland U, Fraunholz I, Kitz J, Rave Fränk M, Wolff HA, Weiss C, Wirtz R, Heinrichs C, Balermpas P, Fokas E, Rödel C. Human papillomavirus load and p16INK4a expression predict for local control in patients with anal squamous cell carcinoma treated with definitive chemoradiotherapy. Int J Cancer 2015;136:278-88.

Bölling T, Weege J, Eich HT, Timmermann B, Meyer FM, Rübe C, Kortmann RD, Fischedick K, Rödel C, Koch R, Willich N. Acute and late side effects to salivary glands and oral mucosa following head/neck radiotherapy in children and adolescents. Head Neck 2015;37:1137-41.

Loutfi-Krauss B, Köhn J, Blümer N, Freundl K, Koch T, Kara E, Scherf C, Rödel C, Ramm U, Licher J. Effect of dose reduction on image registration and image quality for cone-beam CT in radiotherapy. Strahlenther Onkol 2015;191:192-200.

Fokas E, Liersch T, Fietkau R, Hohenberger W, Hess C, Becker H, Sauer R, Wittekind C, Rödel C. Downstage migration after neoadjuvant chemoradiotherapy for rectal cancer: The reverse of the Will Rogers phenomenon? Cancer 2015;121:1724-27.

Maas M, Nelemans PJ, Valentini V, Crane CH, Capirci C, Rödel C, Nash GM, Kuo LJ, Glynne-Jones R, García-Aguilar J, Suárez J, Calvo FA, Pucciarelli S, Biondo S, Theodoropoulos G, Lambregts DM, Beets-Tan RG, Beets GL. Adjuvant chemotherapy in rectal cancer: defining subgroups who may benefit after neoadjuvant chemoradiation and resection A pooled analysis of 3313 patients. Int J Cancer 2015;137:212-20.

Rödel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, Hofheinz RD, Ghadimi M, Wolff HA, Lang-Welzenbach M, Raab HR, Wittekind C, Ströbel P, Staib L, Wilhelm M, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R, Liersch T; German Rectal Cancer Study Group. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2015;16:979-89.

Dornoff N, Weiß C, Rödel F, Wagenblast J, Ghanaati S, Atefeh N, Rödel C, Balermpas P. Re-irradiation with cetuximab or cisplatin-based chemotherapy for recurrent squamous cell carcinoma of the head and neck. Strahlenther Onkol 2015;191:656-664.

Valentini V, van Stiphout RG, Lammering G, Gambacorta MA, Barba MC, Bebenek M, Bonnetain F, Bosset JF, Bujko K, Cionini L, Gerard JP, Rödel C, Sainato A, Sauer R, Minsky BD, Collette L, Lambin P. Selection of appropriate end-points (pCR vs 2yDFS) for tailoring treatments with prediction models in locally advanced rectal cancer. Radiother Oncol 2015;114:302-309.

Specht HM, Ahrens N, Blankenstein C, Duell T, Fietkau R, Gaipl U, Günther C, Gunther S, Habl G, Hautmann H, Hautmann M, Hiber RM, Molls M, Offner R, Rödel C, Rödel F, Schuetz M, Combs SE, Multhoff G. Heat shock protein 70 (Hsp70) peptide activated Natural Killer (NK) cells for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy – from preclinical studies to a clinical phase II trial. Front Immunol 2015;15;6:162.

Hehlgans S, Oppermann J, Reichert S, Fulda S, Rödel C, Rödel F. The SMAC mimetic BV6 sensitizes colorectal cancer cells to ionizing radiation by interfering with DNA repair processes and enhancing apoptosis. Radiation Oncology 2015;10:198.

Large M, Hehlgans S, Reichert S, Gaipl U, Fournier C, Rödel C, Weiss C, Rödel F. Study of the anti-inflammatory effects of low-dose radiation: The contribution of biphasic regulation of the antioxidative system in endothelial cells. Strahlenther Onkol 2015;191:742-749.

Balermpas P, Rödel F, Rödel C, Krause M, Linge A, Lohaus F, Baumann M, Tinhofer I, Budach V, Gkika E, Stuschke M, Avlar M, Grosu AL, Abdollahi A, Debus J, Bayer C, Stangl S, Belka C, Pigorsch S, Multhoff G, Combs SE, Mönnich D, Zips D, Fokas E; DKTK-ROG. CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Int J Cancer 2016;138:171-81.

Linge A, Lock S, Gudziol V, Nowak A, Lohaus F, von Neubeck C, Jutz M, Abdollahi A, Debus J, Tinhofer I, Budach V, Sak A, Stuschke M, Balermpas P, Rödel C, Avlar M, Grosu AL, Bayer C, Belka C, Pigorsch S, Combs SE, Welz S, Zips D, Buchholz F, Aust DE, Baretton GB, Thames H, Dubrovska A, Alsner J, Overgaard J, Baumann M, Krause M. Low CSC marker expression and low hypoxia identify good prognosis subgroups in HPV(-)HNSCC after postoperative radiochemotherapy: a multicenter study of the DKTK-ROG. Clin Cancer Res 2016;22:2639-49.

Tinhofer I, Budach V, Saki M, Konschak R, Niehr F, Jöhrens K, Weichert W, Linge A, Lohaus F, Krause M, Neumann K, Endris V, Sak A, Stuschke M, Balermpas P, Rödel C, Avlar M, Grosu AL, Abdollahi A, Debus J, Belka C, Pigorsch S, Combs SE, Mönnich D, Zips D, Baumann M; DKTK-ROG. Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiation. Eur J Cancer 2016;57:78-86.

Schulze B, Meissner M, Ghanaati S, Burck I, Rödel C, Balermpas P. Hedgehog pathway inhibitor in combination with radiation therapy for basal cell carcinomas of the head and neck: First clinical experience with vismodegib for locally advanced disease. Strahlenther Onkol 2016:192:25-31.

Niyazi M, Pitea A, Mittelbronn M, Steinbach J, Sticht C, Zehentmayr F, Piehlmaier D, Zitzelsberger H, Ganswindt U, Rödel C, Lauber K, Belka C, Unger K. A 4-miRNA signature predicts the therapeutic outcome of glioblastoma. Oncotarget. 2016;7:45764-75.

Bertz S, Wach S, Taubert H, Merten R, Krause FS, Schick S, Ott OJ, Weigert E, Dworak O, Rödel C, Fietkau R, Wullich B, Keck B, Hartmann A. Micropapillary morphology is an indicator of poor prognosis in patients with urothelial carcinoma treated with transurethral resection and radiochemotherapy. Virchows Arch 2016; 469(3):339-44.

Helmke C, Raab M, Rödel F, Matthess Y, Oellerich T, Mandal R, Rödel C, Becker S and Strebhardt K. Ligand stimulation of CD95 induces activation of Plk3 followed by phosphorylation of Caspase-8. Cell Research 2016;26:914-34.

Andratschke N, Parys A, Stadtfeld S, Wurster S, Huttenlocher S, Imhoff D, Yildirim M, Rades D, Rödel C, Dunst J, Hildebrandt G, Blanck O. Clinical results of mean GTV dose optimized robotic guided SBRT for liver metastases. Radiat Oncol 2016;28;11:74

Rödel F, Martin D, Helmke C, Balermpas P, Fokas E, Wieland U, Rave-Fränk M, Kitz J, Matthess Y, Raab M, Strebhardt K, Rödel C. Polo-like kinase 3 and phosphoT273 caspase-8 are associated with improved local tumor control and survival in patients with anal carcinoma treated with concomitant chemoradiotherapy. Oncotarget 2016;7(33):53339-49

Sprenger T, Rothe H, Conradi LC, Beissbarth T, Kauffels A, Kitz J, Homayounfar K, Wolff H, Ströbel P, Ghadimi M, Wittekind C, Sauer R, Rödel C, Liersch T. Stage-Dependent Frequency of Lymph Node Metastases in Patients With Rectal Carcinoma After Preoperative Chemoradiation: Results from the CAO/ARO/AIO-94 Trial and From a Comparative Prospective Evaluation With Extensive Pathological Workup. Dis Colon Rectum 2016;59:377-85.

Sprenger T, Rothe H, Beissbarth T, Conradi L.C., Kauffels A, Homayounfar K, Behnes CL, Rödel C, Liersch T, Ghadimi M. Lymph node metastases in ypT1/2 rectal cancer after neoadjuvant chemoradiotherapy. The Achilles heel of organ-preserving operative procedures? Chirurg 2016;87:593-601.

Linge A, Lohaus F, Löck S, Nowak A, Gudziol V, Valentini C, von Neubeck C, Jütz M, Tinhofer I, Budach V, Sak A, Stuschke M, Balermpas P, Rödel C, Grosu AL, Abdollahi A, Debus J, Ganswindt U, Belka C, Pigorsch S, Combs SE, Mönnich D, Zips D, Buchholz F, Aust DE, Baretton GB, Thames HD, Dubrovska A, Alsner J, Overgaard J, Krause M, Baumann M. HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiother Oncol 2016;121(3):364-73.

Yildirim M, Müller von der Grün J, Winkelmann R, Fokas E, Rödel F, Ackermann H, Rödel C, Balermpas P. Prognostic parameters, p16 and p53 expression in cervical cancer of unknown primary (CUP). A single center  analysis. Strahlenther Onkol 2017;193:305-314.

Hristova Y, Köhn J, Preuß S, Rödel C, Balermpas P. A clinical example of extreme dose exposure for an implanted cardioverter-defibrillator: Beyond the DEGRO guidelines. Strahlenther Onkol, September 2017, Volume 193, Issue 9, pp 756–760

Martin D, Balermpas P, Fokas E, Rödel C, Yildirim M. Are there HIV-specific differences for anal cancer patients treated with standard chemoradiotherapy in the era of combined antiretroviral therapy? Clin Oncol 2017;29:248-55.

Fokas E, Ströbel P, Fietkau R, Ghadimi M, Liersch T, Grabenbauer GG, Hartmann A, Kaufmann M, Sauer R, Graeven U, Hoffmanns H, Raab HR, Hothorn T, Wittekind C_, Rödel C. Tumor regression grading after preoperative chemoradiotherapy as prognostic factor and individual-level surrogate for disease-free survival in rectal cancer. J Natl Cancer Inst 2017, epub ahead of print

Köhn J, Licher J, Loutfi-Krauss B, Mielke M, Blümer N, Scherf C, Heine B; Rödel C, Ramm U. Image movement of the Elekta EPID during gantry rotation: Effects on the verification of dose distributions. Phys Med 2017;34:72-79.

Balermpas P, Rödel F, Krause M, Linge A, Lohaus F, Baumann M, Tinhofer I, Budach V, Sak A, Stuschke M, Gkika E, Grosu A, Abdollahi A, Debus J, Stangl S, Ganswindt U, Belka C, Pigorsch S, Multhoff G, Combs SE, Welz S, Zips D, Lim SY, Rödel C and Fokas E, for the DKTK-ROG. The PD-1/ PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Int J Cancer 2017;141:594-603.

Sprenger T, Beißbarth T, Sauer R, Tschmelitsch J, Fietkau R, Liersch T, Hohenberger W, Staib L, Gaedcke J, Raab R, Rödel C, Ghadimi M. Surgical complications have major prognostic impact in patients with locally advanced rectal cancer: a 10 year follow up analysis of the randomized German rectal cancer trial CAO/ARO/AIO-94. submitted

Rödel F, Steinhäuser K, Kreis N, Friemel A, Martin D, Wieland U, Rave-Fränk M, Balermpas P, Fokas E, Louwen F, Rödel C, Yuan J. Prognostic impact of RITA expression in patients with anal squamous cell carcinoma treated with chemoradiotherapy. Radiother Oncol 2017, in revision

Patterns of failure analysis for breathing motion compensated robotic guided stereotactic body radiation therapy. Strahlenther Oncol 2017;

Martin D, Rödel F, Winkelmann R, Balermpas P, Rödel C, Fokas E. Peripheral leukocytosis is inversely correlated with intratumoral CD8+ T-cell infiltration and associated with worse outcome after chemoradiotherapy in anal cancer. Front Immunol 2017:8;1225

Jiang P, Krockenberger K, Vonthein R, Tereszczuk J, Schreiber A, Liebau S, Huttenlocher S, Imhoff D, Balermpas P, Keller C, Dellas K, Baumann R, Rödel C, Hildebrandt G, Jünemann KP, Merseburger AS, Katz A, Ziegler A, Blanck O, Dunst J. Hypo-fractionated SBRT for localized prostate cancer: a German bi-center single treatment group feasibility trial. Radiat Oncol 2017

Leger S, Zwanenburg A, Pilz K, Lohaus F, Linge A, Zöphel K, Kotzerke J, Schreiber A, Tinhofer I, Budach V, Sak A, Stuschke M, Balermpas P, Rödel C, Ganswindt U, Belka C, Pigorsch S, Combs SE, Mönnich D, Zips D, Krause M, Baumann M, Troost EGC, Löck S, Richter C. A comparative study of machine learning methods for time-to-event survival data for radiomics risk modelling. Sci Rep. 2017

Al-Batran SE, Goetze TO, Mueller DW, Vogel A, Winkler M, Lorenzen S, Novotny A, Pauligk C, Homann N, Jungbluth T, Reissfelder C, Caca K, Retter S, Horndasch E, Gumpp J, Bolling C, Fuchs KH, Blau W, Padberg W, Pohl M, Wunsch A, Michl P, Mannes F, Schwarzbach M, Schmalenberg H, Hohaus M, Scholz C, Benckert C, Knorrenschild JR, Kanngießer V, Zander T, Alakus H, Hofheinz RD, Roedel C, Shah MA, Sasako M, Lorenz D, Izbicki J, Bechstein WO, Lang H, Moenig SP. The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI. BMC Cancer. 2017 Dec 28;17(1):893

Linge A, Schötz U, Löck S, Lohaus F, Neubeck CV, Gudziol V, Nowak A, Tinhofer I, Budach V, Sak A, Stuschke M, Balermpas P, Rödel C, Bunea H, Grosu AL, Abdollahi A, Debus J, Ganswindt U, Lauber K, Pigorsch S, Combs SE, Mönnich D, Zips D, Baretton GB, Buchholz F, Krause M, Belka C, Baumann M; DKTK-ROG. Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC. Radiother Oncol 2017

Förster S, Hehlgans S, Rödel F, Otto B, Cordes N. Radiochemosensitivity and invasion of human colorectal cancer cells is regulated in an α-catenin-independent manner. Int J Oncol 2018

Niyazi M, Adeberg S, Kaul D, Boulesteix AL, Bougatf N, Fleischmann DF, Grün A, Krämer A, Rödel C, Eckert F, Paulsen F, Kessel KA, Combs SE, Oehlke O, Grosu AL, Seidlitz A, Lattermann A, Krause M, Baumann M, Guberina M, Stuschke M, Budach V, Belka C, Debus J. Independent validation of a new reirradiation risk score (RRRS) for glioma patients predicting post-recurrence survival: A multicenter DKTK/ROG analysis. Radiother Oncol 2018;

Stera S, Balermpas P, Chan MKH, Huttenlocher S, Wurster S, Keller C, Imhoff D, Rades D, Dunst J, Rödel C, Hildebrandt G, Blanck O. Breathing-motion-compensated robotic guided stereotactic body radiation therapy : Patterns of failure analysis. Strahlenther Onkol 2018;194:143-155

De-Colle C, Menegakis A, Mönnich D, Welz S, Boeke S, Sipos B, Fend F, Mauz PS, Tinhofer I, Budach V, Abu Jawad J, Stuschke M, Balermpas P, Rödel C, Grosu AL, Abdollahi A, Debus J, Belka C, Ganswindt U, Pigorsch S, Combs SE, Lohaus F, Linge A, Krause M, Baumann M, Zips D; DKTK-ROG. SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy. Radiother Oncol 2018;194:143-155

Martin D, Balermpas P, Winkelmann R, Rödel F, Rödel C, Fokas E. Anal squamous cell carcinoma – State of the art management and future perspectives. Cancer Treat Rev 2018;65:11-21.

Martin D, Rödel C, Fokas E. Nivolumab for pretreated metastatic anal cancer : Immune checkpoint blockade is also advised in combination with radiochemotherapy. Strahlenther Onkol. 2018 Feb. epub ahead of print (Pubmed-Link)

Müller von der Grün J, Martin D , Stöver T ,Ghanaati S, Rödel C, Balermpas P. Chemoradiotherapy as definitive treatment for elderly patients with head and neck cancer. Biomed Res Int. 2018 published online

Rödel F, Steinhäuser K, Nina-Naomi Kreis NN, Friemel A, Martin D, Wieland U, Rave-Fränk M, Balermpas P, Fokas E, Louwen F, Rödel C, Yuan J. Prognostic impact of RITA expression in patients with anal squamous cell carcinoma treated with chemoradiotherapy.  Radiother Oncol 2017

Schmidt S, Linge A, Zwanenburg A, Leger S, Lohaus F, Krenn C, Appold S, Gudziol V, Nowak A, von Neubeck C, Tinhofer I, Budach V, Sak A, Stuschke M, Balermpas P, Rödel C, Bunea H, Grosu AL, Abdollahi A, Debus J, Ganswindt U, Belka C, Pigorsch SU, Combs SE, Mönnich D, Zips D, Baretton GB, Buchholz F, Baumann M, Krause M, Löck S. Development and validation of a gene signature for patients with head and neck squamous cell carcinomas treated by postoperative radio(chemo) therapy. Clin Cancer Res. 2018 epub ahead of print. 

Stangl S, Tontcheva N, Sievert W, Shevtsov M, Niu M, Pigorsch S, Combs S, Haller B, Balermpas P, Rödel F, Rödel C, Fokas E, Krause M, Linge A, Lohhaus F, Baumann M, Tinhofer I, Budach V, Stuschke M, Grosu AL, Abdollahi A, Debus J, Belka C, Lauber K, Mönnich D, Zips D, Multhoff G. Heat shock protein 70 expression and infiltration of CD56+ NK cells as prognostic indicators of survival in patients with squamous cell carcinoma of the head and neck cancer (SCCHN) after adjuvant radiochemotherapy: a multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Int J Cancer 2017

Combs SE, Niyazi M, Adeberg S, Bougatf N, Kaul D, Fleischmann DF, Gruen A, Fokas E, Rödel CM, Eckert F, Paulsen F, Oehlke O, Grosu AL, Seidlitz A, Lattermann A, Krause M, Baumann M, Guberina M, Stuschke M, Budach V, Belka C, Debus J, Kessel KA. Re-irradiation of recurrent gliomas: pooled analysis and validation of an established prognostic score-report of the Radiation Oncology Group (ROG) of the German Cancer Consortium (DKTK). Cancer Med. 2018

Baumann R, Chan MKH, PyschnyF, Stera S, Malzkuhn B, Wurster S, Huttenlocher S, Szücs M, Imhoff D, Keller C,  Balermpas P,  Rades D, Rödel C, Dunst J, Hildebrandt G and Oliver Blanck O. Clinical Results of Mean GTV Dose Optimized Robotic-Guided Stereotactic Body Radiation Therapy for Lung Tumors. Front. Oncol., 17 May 2018 

Moustakis C, Chan MKH, Kim J, Nilsson J, Bergman A, Bichay TJ, Palazon Cano I, Cilla S, Deodato F, Doro R, Dunst J, Eich HT, Fau P, Fong M, Haverkamp U, Heinze S, Hildebrandt G, Imhoff D, de Klerck E, Köhn J, Lambrecht U, Loutfi-Krauss B, Ebrahimi F, Masi L, Mayville AH, Mestrovic A, Milder M, Morganti AG, Rades D, Ramm U, Rödel C, Siebert FA, den Toom W, Wang L, Wurster S, Schweikard A, Soltys SG, Ryu S, Blanck O. Treatment planning for spinal radiosurgery : A competitive multiplatform benchmark challenge. Strahlenther Onkol  2018

Sprenger T, Beißbarth T, Sauer R, Tschmelitsch J, Fietkau R, Liersch T, Hohenberger W, Staib L, Gaedcke J, Raab HR, Rödel C, Ghadimi M. Long-term prognostic impact of surgical complications in the German Rectal Cancer Trial CAO/ARO/AIO-94. Long-term prognostic impact of surgical complications in the German Rectal Cancer Trial CAO/ARO/AIO-94. Br J Surg. 2018

Hess AK, Jöhrens K, Zakarneh A, Balermpas P, von der Grün J, Rödel C, Weichert W, Hummel M, Keilholz U, Budach V, Tinhofer I.  Characterization of the Tumor Immune Micromilieu and its Interference with Outcome After Concurrent Chemoradiation in Patients with Oropharyngeal Carcinomas. Oncoimmunology 2019;8:1614858.

Hess J, Unger K, Maihoefer C, Schüttrumpf L, Wintergerst L, Heider T, Weber P, Marschner S, Braselmann H, Samaga D, Kuger S, Pflugradt U, Baumeister P, Walch A, Woischke C, Kirchner T, Werner M, Werner K, Baumann M, Budach V, Combs SE, Debus J, Grosu AL, Krause M, Linge A, Rödel C, Stuschke M, Zips D, Zitzelsberger HF, Ganswindt U, Henke M, Belka C. A Five-MicroRNA Signature Predicts Survival and Disease Control of Patients with Head and Neck Cancer Negative for HPV-infection. Clin Cancer Res 2019;25:1505-1516.

Merten R, Ott O, Haderlein M, Bertz S, Hartmann A, Wullich B, Keck B, Kühn R, Rödel CM, Weiss C, Gall C, Uter W, Fietkau R. Long-Term Experience of Chemoradiotherapy Combined with Deep Regional Hyperthermia for Organ Preservation in High-Risk Bladder Cancer (Ta, Tis, T1, T2). Oncologist 2019;24:e1341-e1350.

Stera S, Balermpas P, Blanck O, Wolff R, Wurster S, Baumann R, Szücs M, Loutfi-Krauss B, Wilhelm MS, Seifert V, Rades D, Rödel C, Dunst J, Hildebrandtg,  Arnold, A, Meissner M, Kähler, KC. Stereotactic radiosurgery combined with immune checkpoint inhibitors or kinase inhibitors for patients with multiple brain metastases of malignant melanoma. Melanoma Research2019;29:187-195.

Von der Grün J, Köhn J, Loutfi-Krauss B, Blanck O, Rödel C, Balermpas P. Second infield re-irradiation with a resulting cumulative equivalent dose (EQD2max ) of >180 Gy for patients with recurrent head and neck cancer. Head Neck 2019;41:E48-E54.

Voss M, Batarfi A, Steidl E, Wagner M, Forster MT, Steinbach JP, Rödel CM, Bojunga J, Ronellenfitsch MW. Adrenal Insufficiency in Patients with Corticosteroid-Refractory Cerebral Radiation Necrosis Treated with Bevacizumab. J Clin Med 2019;8:pii E1608.

Fokas E, Allgäuer M, Polat B, Klautke G, Grabenbauer GG, Fietkau R, Kuhnt T, Staib L, Brunner T, Grosu AL, Schmiegel W,  Jacobasch L, Weitz J, Folprecht G, Schlenka-Lange A, Flentje M, Germer CT, Grützmann R, Schwarzbach M, Paolucci V, Bechstein WO, Friede T, Ghadimi M, Hofheinz RD, Rödel C, German Rectal Cancer Study Group. Randomized Phase II Trial on Chemoradiotherapy plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12. J Clin Oncol 2019;37:3212-3222.

Fleischmann M, Martin D, Peña-Llopis S, Oppermann J, von der Grün J, Diefenhardt M, Chatzikonstantinou G, Fokas E, Rödel C, Strebhardt K, Becker S, Rödel F, Tselis N. Association of Polo-like kinase 3 and phosphoT273 Caspase 8 with improved survival in patients with cervical squamous cell carcinoma treated with radical chemoradiotherapy and brachytherapy. Front Oncol 2019,9:742.

Diefenhardt M, Hofheinz RD, Martin D, Beissbarth T, Arnold D, Hartmann A, von der Grün J, Grützmann R, Liersch T, Ströbel P, Grabenbauer GG,  Rieger M, Fietkau R, Graeven U, Weitz J, Folprecht G, Ghadimi M, Rödel F, Rödel C, Fokas E. Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIO-04 randomized phase 3 rectal cancer trial. Int J Cancer 2019;145:2282-2291.

Martin D, Rödel F, Balermpas P, Winkelmann R, Fokas E, Rödel C. C-reactive protein-to-albumin ratio as prognostic marker for anal squamous cell carcinoma treated with chemoradiotherapy. Front Oncol 2019;9:1200.

Ludmir EB, Fuller CD, Moningi S, Mainwaring W, Lin TA, Miller AB, Jethanandani A, Espinoza AF, Verma V, Smith BD, Smith GL, VanderWalde NA, Holliday EB, Guadagnolo BA, Stinchcombe TE, Jagsi R, Gomez DR, Minsky BD, Rödel C, Fokas E. Sex-Based Disparities Among Cancer Clinical Trial Participants. J Natl Cancer Inst 2019, epub ahead of print.

Diefenhardt M, Ludmir EB, Hofheinz RD, Ghadimi M, Minsky BD, Rödel C, Fokas E. Association of sex with toxic effects, treatment adherence, and oncologic outcomes in the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 Phase 3 randomized clinical trials of rectal cancer. JAMA Oncol 2019;6:294-96.

Schmidt S, Linge A, Großer M, Lohaus F, Gudziol V, Nowak A, Tinhofer I, Budach V, Sak A, Stuschke M, Balermpas P, Rödel C, Schäfer H, Grosu AL, Abdollahi A, Debus J, Ganswindt U, Belka C, Pigorsch S, Combs SE, Mönnich D, Zips D, Baretton GB, Buchholz F, Baumann M, Krause M, Löck S; DKTK-ROG. Comparison of GeneChip, nCounter and real-time polymerase chain reaction based gene expressions predicting loco-regional tumour control after primary and postoperative radiochemotherapy in head and neck squamous cell carcinoma. J Mol Diagn 2020;801;801-10.

Freund I, Hehlgans S, Martin D, Ensminger M, Fokas E,  Rödel C, Löbrich M, Rödel F. Fractionation-dependent radiosensitization by molecular targeting of Nek1. Cells 2020;9:1235.

Guberina M, Sak A, Pöttgen C, Tinhofer-Keilholz I, Budach V, Balermpas P, Von der Grün J, Rödel CM, Gikka E, Grosu AL, Abdollahi A, Debus J, Belka C, Pigorsch S, Combs S, Mönnich D, Zips D, De-Colle C, Welz S, Linge A, Lohaus F, Baretton G, Gauler T, Baumann M, Krause M, Schuler M, Bankfalvi A, Höing B, Lang S, Stuschke. MERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy. Pharmacogenomics J. 2020; epub ahead of print.

Martin D, Rödel F, von der Grün J, Rödel C, Fokas E. Acute organ toxicity correlates with better clinical outcome after chemoradiotherapy in patients with anal carcinoma. Radiother Oncol 2020;149:168-73.

Voss M, Wagner M, von Mettenheim N, Harter PN, Wenger KJ, Franz K, Bojunga J, Vetter M, Gerlach R, Glatzel M, Paulsen F, Hattingen E, Baehr O, Ronellenfitsch MW, Fokas E, Imhoff D, Steinbach JP, Rödel C, Rieger J. ERGO2: A prospective randomized trial of calorie restricted ketogenic diet and fasting in addition to re-irradiation for malignant glioma. Int J Radiat Oncol Biol Phys 2020; epub ahead of print.

Wenzel M, Humke C, Wicker S, Mani J, Engl T, Hintereder G, Vogl TJ, Wild P, Köllermann J, Rödel C, Asgharie S, Theissen L, Welte M, Kluth LA, Mandel P, Chun FKH, Preisser F, Becker A. Movember health care initiative 2019: prostate cancer screening at the University Hospital Frankfurt. Urologe A 2020; epub ahead of print.

Diefenhardt M, Ludmir EB, Hofheinz RD, Ghadimi M, Minsky BD, Rödel C, Fokas E. Association of Treatment Adherence With Oncologic Outcomes for Patients With Rectal Cancer: A Post Hoc Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial. JAMA Oncol 2020; ahead of print.

Pasalic D, McGinnis GJ, Fuller CD, Grossberg AJ, Verma V, Mainwaring W, Miller AB, Lin TA, Jethanandani A, Espinoza AF, Diefenhardt M, Das P, Subbiah V, Subbiah IM, Jagsi R, Garden AS, Fokas E, Rödel C, Thomas CR Jr, Minsky BD, Ludmir EB. Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials. Eur J Cancer. 2020 Jul 20;136:176-185.

Martin D, von der Grün J, Rödel C, Fokas E. Sarcopenia is associated with hematologic toxicity during chemoradiotherapy in patients with anal carcinoma. Frontiers in Oncology 2020;10:1576.

Multhoff G, Seier S, Stangl S, Sievert W, Shevtsov M, Werner C, Pockley AG, Blankenstein C, Hildebrandt M, Offner R, Ahrens N, Kokowski K, Hautmann M, Rödel C, Fietkau R, Lubgan D, Huber R, Hautmann H, Duell T, Molls M, Specht H, Haller B, Devecka M, Sauter A, Combs SE. Targeted Natural Killer Cell-Based Adoptive Immunotherapy for the Treatment of Patients with NSCLC after Radiochemotherapy: A Randomized Phase II Clinical Trial. Clin Cancer Res. 2020: epub ahead of print.

Kouzy R, Abi Jaoude J, Mainwaring W, Lin TA, Miller AB, Jethanandani A, Espinoza AF, Verma V, Fuller CD, Minsky BD, Rödel C, Taniguchi CM, Ludmir EB. Professional Medical Writer Assistance in Oncology Clinical Trials. Oncologist 2020: epub ahead of print.

Sprenger T, Beißbarth T, Sauer R, Tschmelitsch J, Fietkau R, Hohenberger W, Staib L, Raab HR, Rödel C, Ghadimi M. The long-term influence of hospital and surgeon volume on local control and survival in the randomized German Rectal Cancer Trial CAO/ARO/AIO-94. Surg Oncol 2020;35:200-205

Gambacorta MA, Masciocchi C, Chiloiro G, Meldolesi E, Macchia G, van Soest J, Peters F, Collette L, Gérard JP, Ngan S, Rödel C, Damiani A, Dekker A, Valentini V. Timing to achieve the highest rate of pCR after preoperative radiochemotherapy in rectal cancer: a pooled analysis of 3085 patients from 7 randomized trials. Radiother Oncol 2020; epub ehead of print.

Abi Jaoude J, Kouzy R, Mainwaring W, Lin TA, Miller AB, Jethanandani A, Espinoza AF, Pasalic D, Verma V, VanderWalde NA, Smith BD, Smith GL, Fuller CD, Das P, Minsky BD, Rödel C, Fokas E, Jagsi R, Thomas CR, Subbiah IM, Taniguchi CM, Ludmir EB. Performance Status Restriction in Phase III Cancer Clinical Trials. J Natl Compr Canc Netw. 2020;18:1322-1326.

Wenger KJ, Wagner M, Harter PN, Franz K, Bojunga J, Fokas E, Imhoff D, Rödel C, Rieger J, Hattingen E, Steinbach JP, Pilatus U, Voss M. Maintenance of Energy Homeostasis during Calorically Restricted Ketogenic Diet and Fasting-MR-Spectroscopic Insights from the ERGO2 Trial. Cancers 2020;12:E3549.

Unger K, Fleischmann DF, Ruf V, Felsberg J, Piehlmaier D, Samaga D, Hess J, Suresh MP, Mittelbronn M, Lauber K, Budach W, Sabel M, Rödel C, Reifenberger G, Herms J, Tonn JC, Zitzelsberger H, Belka C, Niyazi M. Improved risk stratification in younger IDH wild-type glioblastoma patients by combining a 4-miRNA signature with MGMT promoter methylation status. Neurooncol Adv 2020;2:vdaa137.

Attenberger UI, Clasen S, Ghadimi M, Grosse U, Antoch G, Schreyer AG, Wessling J, Hausmann D, Piso P, Plodeck V, Stintzing S, Rödel CM, Hofheinz RD. Importance and Qualitative Requirements of Magnetic Resonance Imaging for Therapy Planning in Rectal Cancer - Interdisciplinary Recommendations of AIO, ARO, ACO and the German Radiological Society. Rofo 2021;193:513-520.

Kosmala R, Fokas E, Flentje M, Sauer R, Liersch T, Graeven U, Fietkau R, Hohenberger W, Arnold D, Hofheinz RD, Ghadimi M, Ströbel P, Staib L, Grabenbauer GG, Folprecht G, Kirste S, Uter W, Gall C, Rödel C, Polat B. Quality of life in rectal cancer patients with or without oxaliplatin in the randomised CAO/ARO/AIO-04 phase 3 trial. Eur J Cancer 2021;144:281-290.

Güllülü Ö, Hehlgans S, Mayer BE, Gößner I, Petraki C, Hoffmann M, Dombrowsky MJ, Kunzmann P, Hamacher K, Strebhardt K, Fokas E, Rödel C, Münch C, Rödel F. A spatial and functional interaction of a heterotetramer Survivin-DNA-PKcs complex in DNA damage response. Cancer Res 2021;81:2304-2317.

Pasalic D, Fuller CD, Mainwaring W, Lin TA, Miller AB, Jethanandani A, Espinoza AF, Grossberg AJ, Jagsi R, Das P, Koong AC, Rödel C, Fokas E, Thomas CR Jr, Minsky BD, Ludmir EB. Detecting the Dark Matter of Unpublished Clinical Cancer Studies: An Analysis of Phase 3 Randomized Controlled Trials.Mayo Clin Proc 2021;96:420-426.

Chatzikonstantinou G, Strouthos I, Scherf C, Köhn J, Solbach C, Rödel C, Tselis N. Interstitial multicatheter HDR-brachytherapy as accelerated partial breast irradiation after second breast-conserving surgery for locally recurrent breast cancer. J Radiat Res 2021,62:465-472.

Diefenhardt M, Chatzikonstantinou G, Meissner M, Köhn J, Scherf C, Trommel M, Licher J, Ramm U, Rödel C, Tselis N. HDR brachytherapy with individual epithetic molds for facial skin cancer: techniques and first clinical experience. Int J Dermatol 2021;60:717-723 .

von der Grün J, Winkelmann R, Rödel F, Balster S, Neumayer T, Ghanaati S, Brandts C, Burck I, Martin D, Rödel C, Kesar N, Balermpas P. Patterns of care, toxicity and outcome in the treatment of salivary gland carcinomas: long-term experience from a tertiary cancer center. Eur Arch Otorhinolaryngol 2021; epub ahead of print.

Altay-Langguth A, Balermpas P, Brandts C, Balster S, Ghanaati S, Winkelmann R, Burck I, Rödel F, Martin D, Rödel C, von der Grün J. Re-irradiation with concurrent and maintenance nivolumab in locally recurrent and inoperable squamous cell carcinoma of the head and neck: A single-center cohort study. Clin Transl Radiat Oncol 2021;28:71-78.

Stera S, Miebach G, Buergy D, Dreher C, Lohr F, Wurster S, Rödel C, Marcella S, Krug D, Frank A G, Ehmann M, Fleckenstein J, Blanck O, Boda-Heggemann J. Liver SBRT with active motion compensation results in excellent local control for liver oligometastases: An outcome analysis of a pooled multi-platform patient cohort. Radiother Oncol 2021;158:230-236.

Gambacorta MA, Masciocchi C, Chiloiro G, Meldolesi E, Macchia G, van Soest J, Peters F, Collette L, Gérard JP, Ngan S, Rödel C, Damiani A, Dekker A, Valentini V. Timing to achieve the highest rate of pCR after preoperative radiochemotherapy in rectal cancer: a pooled analysis of 3085 patients from 7 randomized trials. Radiother Oncol  2021;154:154-160.

Scherf C, Licher J, Mletzko C, Trommel M, Tselis N, Chatzikonstantinou G, Diefenhardt M, Rödel C, Köhn J, Ramm U. Individualized mould-based high-dose-rate brachytherapy for perinasal skin tumors: technique evaluation from a dosimetric point of view. J Contemp Brachytherapy 2021;13:179-187.

Haak HE, Beets GL, Peeters K, Nelemans PJ, Valentini V, Rödel C, Kuo L, Calvo FA, Garcia-Aguilar J, Glynne-Jones R, Pucciarelli S, Suarez J, Theodoropoulos G, Biondo S, Lambregts DMJ, Beets-Tan RGH, Maas M. Prevalence of nodal involvement in rectal cancer after chemoradiotherapy. Br J Surg 2021; epub ahead of print

Von der Grün J, Rödel C, Semrau S, Balermpas P, Martin D, Fietkau R, Haderlein M.  Patterns of care analysis for salivary gland cancer: a survey within the German Society of Radiation Oncology (DEGRO) and recommendations for the daily practice. Strahlenther Onkol 2021; accepted.

Voss M, Wenger KJ, von Mettenheim N, Bojunga J, Vetter M, Diehl B, Franz K, Gerlach R, Ronellenfitsch MW, Harter PN, Hattingen E, Steinbach JP, Rödel C, Rieger J. Short-term fasting in glioma patients: analysis of diet diaries and metabolic parameters of the ERGO2 trial. Eur J Nutr 2021 epub ahead of print.

Arnold C, von der Grün J, Brekner M, Licher J, Fokas E, Rödel C, Fleischmann M. Risk stratification by anamnesis increases SARS-CoV-2 test efficiency in cancer patients. Strahlenther Onkol 2021; accepted.

Diefenhardt M, Ludmir EB, Hofheinz RD, Ghadimi M, Minsky BD, Fleischmann M, Fokas E, Rödel C. Impact of body-mass index on treatment and outcome in locally advanced rectal cancer: A secondary, post-hoc analysis of the CAO/ARO/AIO-04 randomized phase III trial. Radiother Oncol 2023;179:109455.

Tawk B, Wirkner U, Schwager C, Rein K, Zaoui K, Federspil PA, Adeberg S, Linge A, Ganswindt U, Hess J, Unger K, Tinhofer I, Budach V, Lohaus F, Krause M, Guberina M, Stuschke M, Balermpas P, Rödel C, Grosu AL, Schäfer H, Zips D, Combs SE, Pigorsch S, Zitzelsberger H, Baumeister P, Kirchner T, Bewerunge-Hudler M, Weichert W, Hess J, Herpel E, Belka C, Baumann M, Debus J, Abdollahi A, Tumor DNA-Methylome derived Epigenetic Fingerprint Identifies HPV-negative Head and Neck Patients at Risk for Locoregional Recurrence after Postoperative Radiochemotherapy. Int J Cancer. 2021; epub ahead of print.

Fokas E, Schlenska-Lange A, Polat B, Klautke G, Grabenbauer GG, Fietkau R, Kuhnt T, Staib L, Brunner T, Grosu AL, Kirste S, Jacobasch L, Allgäuer M, Flentje M, Germer CT, Grützmann R, Hildebrandt G, Schwarzbach M, Bechstein WO, Sülberg H, Friede T, Gaedcke J, Ghadimi M, Hofheinz RD, Rödel C. Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial. JAMA Oncol 2021;18:e215445;epub ahead of print.

Behmüller M, Tselis N, Zamboglou N, Zoga E, Baltas D, Rödel C, Chatzikonstantinou G. High-Dose-Rate Brachytherapy as Monotherapy for Low- and Intermediate-Risk Prostate Cancer. Oncological Outcomes After a Median 15-Year Follow-Up. Front Oncol 2021;11:770959.

Patil S, Tawk B, Grosser M, Lohaus F, Gudziol V, Kemper M, Nowak A, Haim D, Tinhofer I, Budach V, Guberina M, Stuschke M, Balermpas P, Rödel C, Schäfer H, Grosu AL, Abdollahi A, Debus J, Ganswindt U, Belka C, Pigorsch S, Combs SE, Boeke S, Zips D, Baretton GB, Baumann M, Krause M, Löck S, Linge A; DKTK-ROG. Analyses of molecular subtypes and their association to mechanisms ofradioresistance in patients with HPV-negative HNSCC treated bypostoperative radiochemotherapy. Radiother Oncol 2022; epub ahead of print.

Martin D, Schreckenbach T, Ziegler P, Filmann N, Kalinauskaite G, Tinhofer I, Budach V, Gani C, Zips D, Schimek-Jasch T, Schäfer H, Grosu AL, Thomas E, Krause M, Dapper H, Combs S, Hoffmann C, Stuschke M, Walter F, Belka C, Kurth I, Hadiwikarta WW, Baumann M, Rödel C, Fokas E. Evaluation of prognostic factors after primary chemoradiotherapy of anal cancer: A multicenter study of the German Cancer Consortium - Radiation Oncology Group (DKTK-ROG). Radiother Oncol 2022; epub ahead of print.

Nicolas A, Pesic M, Engel E, Paul K. Ziegler P, Diefenhardt M, Kennel KB, Büttner F, Conche C, Petrocelli V, Elwakeel E, Weigert A, Zinoveva A, Fleischmann M, Häupl B, Karakütük C, Bohnenberger H, Mosa M, Kaderali L, Gaedcke J, Ghadimi M, Rödel F, Arkan MC, Oellerich T, Rödel C, Fokas E, Greten FR. Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer. Cancer Cell 2022;40:1-17.

Von Der Grün J, Winkelmann R, Burck I, Martin D, Rödel F, Wild PJ, Bankov K, Weigert A, Kur IM, Brandts C, Filmann N, Issing C, Thönissen P, Tanneberger AM, Rödel C, Ghanaati S, Balermpas P. Neoadjuvant chemoradiotherapy for oral cavity cancer: Predictive factors for response and interim analysis of the prospective INVERT-Trial. Front Oncol 2022;12:817692.

Scherf C, Ramm U, Stein T, Trommel M, Tselis N, Chatzikonstantinou G, Diefenhardt M, Rödel C, Köhn J, Licher J. Effects of iodinated contrast agent on HU-based dose calculation and dose delivered in iridium-192 high-dose-rate brachytherapy. J Contemp Brachytherapy 2022;14:80-86.

Sieker K, Fleischmann M, Trommel M, Ramm U, Licher J, Bug G, Martin H, Serve H, Rödel C, Balermpas P. Twenty years of experience of a tertiary cancer center in total body irradiation with focus on oncological outcome and secondary malignancies. Strahlenther Onkol 2022;198:547-557.

Frey A, Martin D, D'Cruz L, Fokas E, Rödel C, Fleischmann M. C-Reactive Protein to Albumin Ratio as Prognostic Marker in Locally Advanced Non-Small Cell Lung Cancer Treated with Chemoradiotherapy. Biomedicines 2022;10(3):598.

Osong B, Masciocchi C, Damiani A, Bermejo I, Meldolesi E, Chiloiro G, Berbee M, Lee SH, Dekker A, Valentini V, Gerard JP, Rödel C, Bujko K, van de Velde C, Folkesson J, Sainato A, Glynne-Jones R, Ngan S, Brændengen M, Sebag-Montefiore D, van Soest J. Bayesian network structure for predicting local tumor recurrence in rectal cancer patients treated with neoadjuvant chemoradiation followed by surgery. Phys Imaging Radiat Oncol 2022;22:1-7.

Fleischmann M, Diefenhardt M, Trommel M, Scherf C, Ramm U, Chatzikonstantinou G, Fokas E, Rödel C, Tselis N. Image-guided high-dose-rate brachytherapy for rectal cancer: technical note and first clinical experience on an organ-preserving approach. Strahlenther Onkol 2022;198:654-662.

Zoga E, Wolff R, Ackermann H, Meissner M, Rödel C, Tselis N, Chatzikonstantinou G. Factors Associated with Hemorrhage of Melanoma Brain Metastases after Stereotactic Radiosurgery in the Era of Targeted/Immune Checkpoint Inhibitor Therapies. Cancers 2022;14:2391.

Shahzadi I, Zwanenburg A, Lattermann A, Linge A, Baldus C, Peeken JC, Combs SE, Diefenhardt M, Rödel C, Kirste S, Grosu AL, Baumann M, Krause M, Troost EGC, Löck S. Analysis of MRI and CT-based radiomics features for personalized treatment in locally advanced rectal cancer and external validation of published radiomics models. Sci Rep 2022;12:10192.

Wichtmann BD, Albert S, Zhao W, Maurer A, Rödel C, Hofheinz RD, Hesser J, Zöllner FG, Attenberger UI Are We There Yet? The Value of Deep Learning in a Multicenter Setting for Response Prediction of Locally Advanced Rectal Cancer to Neoadjuvant Chemoradiotherapy. Diagnostics 2022;12:1601.

Emons G, Auslander N, Jo P, Kitz J, Azizian A, Hu Y, Hess CF, Roedel C, Sax U, Salinas G, Stroebel P, Kramer F, Beissbarth T, Grade M, Ghadimi M, Ruppin E, Ried T, Gaedcke J. Gene-expression profiles of pretreatment biopsies predict complete response of rectal cancer patients to preoperative chemoradiotherapy. Br J Cancer 2022;127:766-775.

Diefenhardt M, Schlenska-Lange A, Kuhnt T, Kirste S, Piso P, Bechstein WO, Hildebrandt G, Ghadimi M, Hofheinz RD, Rödel C, Fokas E. Total Neoadjuvant Therapy for Rectal Cancer in the CAO/ARO/AIO-12 Randomized Phase 2 Trial: Early Surrogate Endpoints Revisited. Cancers 2022;14:3658.

Diefenhardt M, Martin D, Ludmir EB, Fleischmann M, Hofheinz RD, Ghadimi M, Kosmala R, Polat B, Friede T, Minsky BD, Rödel C, Fokas E. Development and Validation of a Predictive Model for Toxicity of Neoadjuvant Chemoradiotherapy in Rectal Cancer in the CAO/ARO/AIO-04 Phase III Trial. Cancers 2022;14:4425

Fleischmann M, Mandal R, Kostova I, Raab M, Sanhaji M, Hehlgans S, Diefenhardt, Fokas E, Rödel C, Strebhardt K. Rödel F. Prognostic impact of caspase-8, CDK9 and phospho-CDK9 (Thr 186) expression in patients with uterine cervical cancer treated with definitive chemoradiation and brachytherapy. Cancers 2022;14:5500.

Chatzikonstantinou G, Diefenhardt M, Fleischmann M, Meissner M, Scherf C, Trommel M, Ramm U, Rödel C, Tselis N, Licher J. Customized 3D-printed molds for high dose-rate brachytherapy in facial skin cancer: First clinical experience. J Dtsch Dermatol Ges 2023;21:35-41.

Krug D, Imhoff D, Haidenberger A, Heßler N, Schäfer J, Huttenlocher S, Chatzikonstantinou G, Fürweger C, Ramm U, König IR, Chun F, Staehler M, Rödel C, Muacevic A, Vonthein R, Dunst J, Blanck O.Robotic stereotactic body radiotherapy for localized prostate cancer: final analysis of the German HYPOSTAT trial. Strahlenther Onkol 2023;199:565-573.

Gambacorta MA, Chiloiro G, Masciocchi C, Mariani S, Romano A, Gonnelli A, Gerard JP, Ngan S, Rödel C, Bujko K, Glynne-Jones R, van Soest J, Dekker A, Damiani A, Valentini V. pCR and 2-Year Disease-Free Survival: A Combination of the Two Endpoints as a New Classification for Locally Advanced Rectal Cancer Patients-An Updated Pooled Analysis of Eleven International Randomized Trials. Cancers 2023;15:3209.

Tawk B, Rein K, Schwager C, Knoll M, Wirkner U, Hörner-Rieber J, Liermann J, Kurth I, Balermpas P, Roedel C, Linge A, Loeck S, Lohaus F, Tinhofer I, Krause M, Stuschke M, Grosu AL, Zips D, Combs SE, Belka C, Stenzinger A, Herold-Mende C, Baumann M, Schirmacher P, Debus J, Abdollahi ADNA-Methylome based Tumor Hypoxia Classifier Identifies HPV-negative Head & Neck Cancer Patients at Risk for Locoregional Recurrence After Primary Radiochemotherapy. Clin Cancer Res 2023; epub ahead of print.

Wenzel M, Garcia CC, Hoeh B, Jorias C, Humke C, Koll F, Tselis N, Rödel C, Graefen M, Tilki D, Chun FKH, Mandel P. Real-world evidence of outcomes of oligometastatic hormone-sensitive prostate cancer patients treated with metastasis-directed therapy. Prostate 2023 epub ahead of print.

Schuettfort G, Roether C, Berger A, Fokas E, Fraunholz I, Groh A, Haberl A, Khaykin P, Martin D, Roedel C, Vehreschild M, Stephan C. Differences in the course of CD4 and CD8 cells after chemoradiotherapy in PLWH with anal cancer. AIDS Res Hum Retroviruses 2023; epub ahead of print.

Sauer R, Rödel C. Heilung in heilloser Welt. Herausforderung der Bioethik an Theologie und Kirche. Nachrichten 1996, 51:1-5.

Rödel C, Hohenberger W, Sauer R. Adjuvante und neoadjuvante Therapie des Rektumkarzinoms. Aktueller Stand. Strahlenther Onkol 1998;174:497-504.

Rödel C, Hohenberger W, Sauer R. Welcher Patient mit Rektumkarzinom benötigt eine neoadjuvante Radiotherapie? Chir Gastroenterol 2000;16:260-266.

Dunst J, Rödel C, Zietman A, Schrott KM, Sauer R, Shipley WU. Bladder preservation in muscle-invasive bladder cancer by conservative surgery and radiochemotherapy. Surg Oncol 2001;20:24-32.

Rödel C, Sauer R. Perioperative radiotherapy and concurrent radiochemotherapy in rectal cancer. Surg Oncol 2001;20:3-12.

Dunst J, Rödel C, Diestelhorst A, Heyemann H, Schrott KM, Sauer R. Radiochemotherapy for T1G3-bladder cancer. Front Radiat Ther Oncol 2002, 36:151-58.

Sauer R, Rödel C. Adjuvante und neoadjuvante Radiochemotherapie des Rektumkarzinoms. Praxis (Schweizer Rundschau für Medizin) 2002;91:1476-1484.

Durek C, Rödel C, Jocham D. Klinische Diagnostik und Therapie des oberflächlichen Blasenkarzinoms. Onkologe 2002;8:929-39.

Rödel C, Hagan MP, Sauer R. Bladder Cancer – The combination of chemotherapy and irradiation in the treatment of patients with invasive bladder cancer. CD-ROM, ASTRO-Refresher Course Syllapi 2002

Rödel C. TME: Macht sie die Strahlentherapie überflüssig? Dtsch Med Wochenschr 2003;128:118-20.

Sauer R, Rödel C. Adjuvante und neoadjuvante Radiochemotherapie des Rektumkarzinoms. In: Klinische Onkologie 2004/2005 (Symposiumsband, S.L. Roth, Hrsg.) 2004;191-196.

Rödel C, Sauer R. Organerhalt durch Radiochemotherapie beim invasiven Blasenkarzinom. In: Klinische Onkologie 2004/2005 (Symposiumsband, S.L. Roth, Hrsg.) 2004;240-44.

Sauer R, Rödel C. Die Rolle der Radiochemotherapie bei der Behandlung des Harnblasenkarzinoms. Der Onkologe 2004 (Suppl 1)10:16-18.

Rödel C, Sauer R. Neoadjuvant radiochemotherapy in rectal cancer: for which patients and tumor stages? Front Radiat Ther Oncol 2004;38:13-23.

Rödel C, Sauer R. Radiotherapy and concurrent radiochemotherapy for rectal cancer. Surg Oncol 2004;13:93-101.

Hohenberger W, Rödel C, Merkel S. Kolorektales Karzinom. Endoskopie heute 2004;17:97-103.

Rödel C, Sauer R. Adjuvante, neoadjuvante und palliative Radiotherapie und Radiochemotherapie des Rektumkarzinoms. Verdauungskrankheiten 2004;4: 223-30.

Rödel C. Current status of radiation therapy and combined modality treatment for bladder cancer. Strahlenther Onkol 2004;180:701-709.

Rödel C, Weiss C, Sauer R. Organ preservation by combined modality treatment in bladder cancer: The European perspective. Semin Radiat Oncol 2005;15:28-35.

Rödel C, Sauer R. What is the role of radiotherapy in bladder-preserving cancer therapy? Nature Clinical Practice Oncology 2005;2:4-5.

Goebell PJ, Vom Dorp F, Rödel C, Frohneberg D, Thuroff JW, Jocham D, Stief C, Roth S, Knuchel R, Schmidt KW, Kausch I, Zaak D, Wiesner C, Miller K, Sauer R, Rübben H. Noninvasive and invasive bladder cancer: diagnostics and treatment. Urologe 2006;45:873-85.

Rödel C. Rektumkarzinom: Neoadjuvante/adjuvante Radiochemotherapie und Differentialtherapie. Journal Onkologie 2006;3:12-14.

Rödel C, Weiss C, Sauer R. Trimodality treatment and selective organ preservation for bladder cancer. J Clin Oncol 2006;24:5536-44.

Rödel C, Sauer R. Neoadjuvante Radiotherapie und Radiochemotherapie beim Rektumkarzinom: Standards und Ausblick. Vizeralchirurgie 2006;41:333-7.

Stief C, Zaak D, Stöckle M, Studer U, Knuechel R, Rödel C, Sauer R, Rübben H. Standards und Perspektiven in der Diagnostik und Therapie des Harnblasenkarzinoms. Urologe A 2006;45:90-6

Milosevic M, Gospodarowicz M, Zietman A, Abbas F, Haustermans K, Moonen L, Rödel C, Schoenberg M, Shipley W. Radiotherapy for bladder cancer. Urology 2007;69:80-92.

Rödel C, Sauer R. Integration of novel agents into combined modality treatment for rectal cancer patients. Strahlenther Onkol 2007;183:227-35.

Sauer R, Tannapfel A, Rödel C, Hölscher A, Fietkau R, Vanhoefer U, Trarbach T. Die Therapie des Rektumkarzinoms. Onkologie 2007;30:18-22.

Höhler T, Rödel C, Hölscher A, Al-Batran SE. Neoadjuvante und palliative Therapie des Ösophagus- und Magenkarzinoms. Onkologie 2007;30:23-26.

Rödel C, Weiss C, Sauer R. Radiochemotherapie des Harnblasenkarzinoms. Der Onkologe 2007;13:1096-100.

Capalbo G, Rödel C, Stauber R, Knauer SK, Bache M, Kappler M, Rödel F. The role of survivin for radiation therapy: prognostic and predictive factor and therapeutic target. Strahlenther Onkol 2007;183:593-9

Rödel C, Weiss C, Sauer R. Combined systemic therapy and radiotherapy for bladder cancer. Strahlenther Onkol 2007,183(Sondernr.2):29-31.

Weiss C, Sauer R, Rödel C. Radiochemotherapeutische Optionen beim Harnblasen- karzinom. Aktuelle Urol 2008;39:123-9.

Weiss C, Ott O, Wittlinger M, Krause SF, Fietkau R, Sauer R, Rödel C. Treatment options for high-rsik T1 bladder cancer: Status quo and future perspectives of radiochemotherapy. Strahlenther Onkol 2008, 184:443-9.

Rödel C. Radiotherapie und Radiochemotherapie beim Rektumkarzinom. Der Gastro- enterologe. 2008, 3:216-34

Valentini V, Beets-Tan R, Borras JM, Krivokapic Z, Leer JW, Pahlman L, Rödel C, Schmoll HJ, Scott N, Van der Velde C, Verfaillie C. Evidence and research in rectal cancer. Radiother Oncol 2008,87:449-74.

Schmiegel W, Reinacher-Schick A, Arnold D, Graeven U, Heinemann V, Porschen R, Riemann J, Rödel C, Sauer R, Wieser M, Schmitt W, Schmoll HJ, Seufferlein T, Kopp I, Pox C. S3-Leitlinie „Kolorektales Karzinom“– Aktualisierung 2008. Z Gastroenterol 2008;46:799-840.

Rödel C. Radiation therapy combined with novel chemotherapy regiments and targeted agents for patients with rectal cancer. Am Soc Clin Oncol Ed Book 146-151, 2008.

Rödel C, Schmiegel W. Rektumkarzinom. Best Practice Onkologie 2008;3:4-15

Rödel C, Höhler T, Sauer R, Siewczynski R, Flentje M, Budach V, Schlag PM. Multimodality treatment for colorectal cancer. Onkologie 2008;31 Suppl.5:4-8.

Marquard F, Rödel F, Capalbo G, Weiss C, Rödel C. Molecular targeted treatment and radiation therapy for rectal cancer. Strahlenther Onkol, 2009;185:371-78.

Ott OJ, Rödel C, Weiss C, Wittlinger M, Dunst J, Fietkau R, Sauer R. Radiochemotherapy for bladder cancer. Clinical Oncology (R Coll Radiol), 2009; 21:557-65.

Rödel C, Knöfel WT, Schlitt HJ, Staib L, Höhler T. Neoadjuvant and surgical treatment for rectal cancer. Onkologie 2009;32 (suppl 2) 17-20.

Hegewisch-Becker S, Vanhoefer U, Kubicka S, Pech M, Moehler M, Riess H, Hartmann JT, Malek N, Rödel C, Arnold D. Palliative treatment for colorectal cancer. Onkologie 2009;32 (suppl 2) 3-6.

Rödel C, Sauer R, Fietkau R. The role of magnetic resonance imaging to select patient for preoperative treatment in rectal cancer. Strahlenther Onkol 2009;185:488-92.

Rödel C. Strahlentherapeutische Aspekte der Behandlung des Kolonkarzinoms. Onkologe 2009;15:1235-8

Rödel C. Molekular-zielgerichtete Therapieansätze in der multimodalen Behandlung des Rektumkarzinoms. Onkologie heute 2009;5:43-45.

Grundmann RT, Hölscher AH, Bembenek E, Drognitz O, Feuerbach S, Gastlinger I, Hermanek P, Hopt UT, Hünerbein M, Illerhaus G, Junginger T, Kraus M, Meining A, Merkel S, Meyer HJ, Mönig SP, Piso P, Roder J, Rödel C, Tannapfel A, Wittekind C, Woeste G. Diagnostik und Therapie des Magenkarzinoms – Workflow. Zentralbl Chir 2009;134:362-74.

Schmiegel W, Reinacher-Schick A, Graeven U, Porschen R, Rödel C, Arnold D. S3-Leitlinie „Kolorektales Karzinom“– Kurzfassung. Dtsch Arztebl Int. 2009 106(51-52):843-8.

Hermanek P, Merkel S, Fietkau R, Rödel C, Hohenberger W. Regional lymph node metastasis and locoregional recurrences of rectal cancer in the era of TME surgery. Implications for treatment decisions. Int J Colorectal Dis 2010; 25:359-68.

Rödel C. Preoperative chemoradiotherapy for rectal cancer. Nat Rev Clin Oncol 2010;7:129-30.

Schmiegel W, Pox C, Reinacher-Schick A, Adler G, Arnold D, Fleig W, Fölsch UR, Frühmorgen P, Graeven U, Heinemann V, Hohenberger W, Holstege A, Junginger T, Kopp I, Kühlbacher T, Porschen R, Propping P, Riemann JF, Rödel C, Sauer R, Sauerbruch T, Schmitt W, Schmoll HJ, Seufferlein T, Zeitz M, Selbmann HK. S3 guidelines for colorectal carcinoma: results of an evidence-based consensus conference on February 6/7, 2004 and June 8/9, 2007 (for the topics IV, VI and VII). Z Gastroenterol. 2010;48:65-136.

Minsky BD, Rödel C, Valentini V. Combined modality treatment for rectal cancer. Cancer J 2010;16(3):253-61.

Rödel C, Bruch HB, Hofheinz R, Lang H, Arnold D. Treatment of rectal cancer. Onkologie 2010;33:19-23.

Rödel C. Radiochemotherapy of anal cancer. Onkologie 2010;33:24-25.

Weiss C, Rödel C. Alternatives for radical cystectomy in non-muscle invasive bladder cancer. Nat Rev Clin Oncol 2010;7:307-8

Rödel C. Current status and future directions in preoperative chemoradiotherapy of rectal cancer. Am Soc Clin Oncol Ed Book 2010,131-35.

Fraunholz I, Rabeneck D, Weiss C, Rödel C. Combined modality treatment for anal cancer: current strategies and future directions. Strahlenther Onkol 2010; 186:361-66.

Kreis ME, Junginger T, Rödel C, Heinemann V, Mansmann U, Jauch KW. Das Optimult Studienkonzept – Grundlage für selektiven Einsatz neoadjuvanter Radiochemotherapie auf MRT-Basis. Zentralbl Chirurgie 2010;135:302-306.

Rödel C, Arnold D, Becker H, Fietkau R, Ghadimi M, Graeven U5, Hess C, Hofheinz R, Hohenberger W, Post S, Raab R, Sauer R, Wenz F, Liersch T. Induction chemotherapy before chemoradiotherapy and surgery for rectal cancer: Is it time for a randomized phase III trial? Strahlenther Onkol 2010, 186:658-64.

Sautter-Bihl ML, Sedlmayer F, Budach W, Dunst J, Engenhardt-Cabillic  R, Fietkau R, Feyer P, Haase W, Harms W, Rödel C, Souchon R, Wenz F, Sauer R. Intraoperative radiotherapy as accelerated partial breast irradiation for early breast cancer - Beware of one-stop-shops? Strahlenther Onkol 2010, 186:651-57.

Rödel F, Reichert S, Sprenger T, Gaibl US, Mirsch J, Liersch T, Fulda S, Rödel C. The role of survivin in radiation oncology: moving beyond apoptosis inhibition. Current Medicinal Chemistry 2011;18:191-99.

Arnold D, Fietkau R, Hegewisch-Becker S, Höhler T, Knoefel WT, Kubicka S, Lang H, Liersch T, Luster M, Oettle H, Reinacher-Schick A, Ridwelski K, Riess H, Rödel C, Rüschoff J, Schmiegel W, Schmoll HJ, Vanhoefer U. Gastrointestinale Tumore – interdisziplinäre Diskussion neuer Daten. Onkologie 2011;34 Suppl 3:1-31.

Gaedke J, Liersch T, Hess CF, Becker H, Rödel C, Ghadimi M. Rektumkarzinom: Aktueller Stand der multimodalen Therapie – wann und wie? Zentralbl Chirurgie 2011;136:334-42.

Niyazi M, Maihöfer C, Krause M, Rödel C, Budach W, Belka C. Radiotherapy and „new“ drugs – new side effects? Radiat Oncol 2011; 21,6:177.

Senf B, Franz K, Skorda I, Rödel C, Steinbach J, Bähr O. Psychoonkologische Behandlungsindikationen und Therapieansätze bei hirneigenen Tumoren. Nervenheilkunde 2012;31:630-3

Rödel F, Frey B, Gaipl U, Keilholz L, Fournier C, Manda K, Schöllnberger H, Hildebrand G, Rödel C. Modulation of inflammatory immune reactions by low-dose ionizing radiation: molecular mechanisms and clinical applications. Current Medicinal Chemistry 2012;19:1741-50.

Rödel F, Sprenger T, Kaina B, Liersch T, Rödel C, Fulda S, Hehlgans S. Survivin as a prognostic/predictive molecular marker and therapeutic target in cancer therapy. Current Medicinal Chemistry 2012;19:3679-88.

Rödel C. Strahlentherapie des Rektumkarzinoms. Onkologie heute 2012;2: 17-20.

Rödel C, Hofheinz R, Liersch T. Rectal cancer: state of the art in 2012. Curr Opin Oncol 2012;24:441-47.

Sautter-Bihl ML, Sedlmayer F, Budach W, Dunst J, Feyer P, Fietkau R, Haase W, Harms W, Rödel C, Souchon R, Wenz F, Sauer R. One life saved by four prevented recurrences? Update of the Early Breast Cancer Trialists confirms: postoperative radiotherapy improves survival after breast conserving surgery. Strahlenther Onkol 2012;188:461-463.

Minsky B, Rödel C, Valentini V. Short Course Radiation vs. Long Course Chemoradiation for Rectal Cancer. The Journal of the National Comprehensive Cancer Network 2012;10:1223-31.

Weiss C, Rödel C. Chemoradiation superior in muscle-invasive bladder cancer. Nat Rev Clin Oncol 2012;9:374-5.

Hofheinz R, Liersch T, Rödel C. Perioperative Therapie des lokal fortgeschrittenen Rektumkarzinoms. Onkologe 2012;18:923-26.

Rödel C, Trojan J, Bechstein WO, Woeste G. Neoadjuvant short- or long-term radio(chemo-)therapy for rectal cancer: How and who should be treated? Dig Dis 2012, 30:102-108

Rödel F, Frey B, Manda K, Hildebrandt G, Hehlgans S, Keilholz L, Seegenschmiedt MH, Gaipl US, Rödel C. Immunomodulatory properties and molecular effects in inflammatory diseases of low-dose x-irradiation. Front Oncol 2012;2:120.

Sautter-Bihl ML, Sedlmayer F, Budach W, Dunst J, Feyer P, Fietkau R, Haase W, Harms W, Rödel C, Souchon R, Wenz F, Sauer R. When are breast cancer patients old enough for the quitclaim of local control? Strahlenther Onkol 2012, 188:1069-73.

Weiss C, Sauer R, Rödel C. Stellenwert der Radiochemotherapie beim Harnblasenkarzinom. Onkologe 2012;18:1003-11

Fokas E, Steinbach JP, Rödel C. Biology of brain metastases and novel targeted therapies: Time to translate the research. Biochim Biophys Acta 2012;1835:61-75.

Fokas E, Weiss C, Rödel C. The role of radiotherapy in the multimodal management of esophageal cancer. Digestive Diseases 2013;31(1):30-37.

Sautter-Bihl ML, Hohenberger W, Fietkau R, Rödel C, Schmidberger H, Sauer R. Rectal cancer : When is the local recurrence risk low enough to refrain from the aim to prevent it? Strahlenther Onkol 2013;189:105-10

Sedlmayer F, Sautter-Bihl ML, Budach W, Dunst J, Feyer P, Fietkau R, Haase W, Harms W, Rödel C, Souchon R, Wenz F, Sauer R. s the simultaneously integrated boost (SIB) technique for early breast cancer ready to be adopted for routine adjuvant radiotherapy? : Statement of the German and the Austrian Societies of Radiooncology (DEGRO/ÖGRO). Strahlenther Onkol 2013 189:193-97.

van de Velde CJ, Aristei C, Boelens PG, Beets-Tan RG, Blomqvist L, Borras JM, van den Broek CB, Brown G, Coebergh JW, Cutsem EV, Espin E, Gore-Booth J, Glimelius B, Haustermans K, Henning G, Iversen LH, Han van Krieken J, Marijnen CA, Mroczkowski P, Nagtegaal I, Naredi P, Ortiz H, Påhlman L, Quirke P, Rödel C, Roth A, Rutten HJ, Schmoll HJ, Smith J, Tanis PJ, Taylor C, Wibe A, Gambacorta MA, Meldolesi E, Wiggers T, Cervantes A, Valentini V. EURECCA colorectal: Multidisciplinary Mission statement on better care for patients with colon and rectal cancer in Europe. Eur J Cancer 2013;49:2784-90.

Weiss Ch, Schulze B, Ottinger A, Rödel C. To combine or not to combine: the role of radiotherapy and targeted agents in the treatment of renal cell carcinoma. World J Urol 2014 Feb;32(1):59-67

Sautter-Bihl ML, Hohenberger W, Fietkau R, Roedel C, Schmidberger H, Sauer R. MRI-Based Treatment of Rectal Cancer: Is Prognostication of the Reccurence Risk Solid Enough to Render Radiation Redundant? Ann Surg Oncol. 2014;21:197-204.

Valentini V, Glinelius B, Haustermans K, Marijnen CA, Rödel C, Gambacorta MA,Boelens PG, Aristei C, van de Velde CJ. EURECCA consensus conference highlights about rectal cancer clinical management: The radiation oncologist's expert review. Radiother Oncol. 2014;110:195-8.

Ploussard G, Daneshmand S, Efstathiou JA, Herr HW, James ND, Rödel CM, Shariat SF, Shipley WU, Sternberg CN, Thalmann GN, Kassouf W. Critical Analysis of Bladder Sparing with Trimodal Therapy Trimodal Therapy in Muscle-invasive Bladder Cancer: A Systematic Review. Eur Urol. 2014;66:120-137

van de Velde CJ, Boelens PG, Borras JM, Coebergh JW, Cervantes A, Blomqvist L, Beets-Tan RG, van den Broek CB, Brown G, Van Cutsem E, Espin E, Haustermans K, Glimelius B, Iversen LH, van Krieken JH, Marijnen CA, Henning G, Gore-Booth J, Meldolesi E, Mroczkowski P, Nagtegaal I, Naredi P, Ortiz H, Påhlman L, Quirke P, Rödel C, Roth A, Rutten H, Schmoll HJ, Smith JJ, Tanis PJ, Taylor C, Wibe A, Wiggers T, Gambacorta MA, Aristei C, Valentini V. EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum. Eur J Cancer. 2014;50(1):1.e1-1.e34

Minsky BD, Rödel C, Valentini V. Preoperative Therapy for Rectal Cancer: Short Course Radiation vs. Long Course Chemoradiation. Preoperative therapy for rectal cancer: Short-course radiation vs. long-course chemoradiation. Seminars in Colon & Rectal Surgery. 2014;25:19-21

Balermpas P, Rödel F, Weiss C, Rödel C, Fokas E. Tumor-infiltrating lymphocytes favor the response to chemoradiotherapy of head and neck cancer. Oncoimmunology. 2014;3:e27403.

Bergs J, Wacker M, Hehlgans S, Piiper A, Multhoff G, Rödel C, Rödel F. The role of recent nanotechnology in enhancing the efficacy of radiation therapy. Biochim Biophys Acta 2015;1856:130-143.

Fokas E, Rödel C. Definitive, preoperative, and palliative radiation therapy of oesophageal cancer. Viszeralmedizin 2015;31:347-53.

Rödel C, Hofheinz RD, Fokas E. Rectal Cancer: neoadjuvant chemoradiotherapy. Best Pract Res Clin Gastroenterol 2016;30:629-639

Trojan J, Bechstein WO, Vogl T, Rödel C, Woeste G. Diagnostik und Therapie des kolorektalen Karzinoms – Fortschritte durch Interdiziplinarität. Hessisches Ärzteblatt 2015;6:330-34.

Fokas E, Rödel C. Targeted agents in GI radiotherapy: Clinical efficacy and side effects. Best Pract Res Clin Gastroenterol 2016;30:537-549

Rödel C. ASTRO Clinical Practice Statement for the appropriate customization of radiation therapy for rectal cancer: A European perspective. Pract Radiat Oncol 2016.

Tselis N, Hoskin P, Baltas D, Strnad V, Zamboglou N, Rödel C, Chatzikonstantinou G. High-dose-rate brachytherapy as monotherapy for localised prostate cancer: Review of the current status. Clin Oncol 2017;29:401-11.

Hypo-fractionated radiosurgery for localized prostate cancer: A German bi-center single treatment group feasibility trial. BMC Cancer 2016, submitted

Müller von der Grün J, Tahtali A, Ghanaati S, Rödel C, Balermpas P. Diagnostic and treatment modalities for patients with cervical lymph node metastases of unknown primary site - current status and challenges. Radiat Oncol 2017, 10;12(1):82.

Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rödel C, Cervantes A,  Arnold D. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017

Gani C, Bonomo P, Zwirner K, Menegakis A, Rödel C, Zips D. Organ preservation in rectal cancer – Challenges and future strategies. Clinical and Translational Radiation Oncology 2017

Chatzikonstantinou G, Zamboglou N, Rödel C, Zoga E, Strouthos I, Ahmed Butt S, Tselis N. Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer after definitive radiotherapy: A systematic review. Strahlenther Onkol 2017

Martin D, Rödel F, Balermpas P, Rödel C, Fokas E. The immune microenvironment and HPV in anal cancer: Rationale to complement chemoradiation with immunotherapy. BBA – Reviews on Cancer 2017; 10;1868(1):221-230.

Rödel F, Fournier C, Wiedemann J, Merz F, Gaipl U, Frey B, Keilholz L, Seegenschmidt MH, Rödel C, Hehlgans S. Basics of radiation biology when treating hyperproliferative benign diseases. Frontiers in Immunology 2017; 3;8:519

Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rödel C, Cervantes A, Arnold D; ESMO Guidelines Committee. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 1;28(suppl_4):iv22-iv40

Von der Grün J, Rödel F, Fokas E, Guckenberger M, Rödel C, Brandts C, Balermpas P. Targeted therapies and immune-checkpoint inhibition in head and neck squamous cell carcinoma: Where do we stand and where to go. Cancers 2019;11:472.

Rödel F, Martin D, Balermpas P, Wieland U, Winkelmann R, Riekmann T, Falk S, Rödel C, Fokas E. Modulation of radiation sensitivity and antitumor immunity by viral pathogenic factors: Implications for radio-immunotherapy. Biochim Biophys Acta Rev Cancer  2019;1871:126-137.

Gani C, Gani N, Zschaeck S, Eberle F, Schaeffeler N, Hehr T, Berger B, Fischer SG, Claßen J, Zipfel S, Rödel C, Teufel M, Zips D. Organ Preservation in Rectal Cancer: The Patients' Perspective. Front Oncol 2019;10;9:318.

Valentini V, Marijnen C, Beets G, Bujko K, De Bari B, Cervantes A, Chiloiro G, Coco C, Gambacorta MA, Glynne-Jones R, Haustermans K, Meldolesi E, Peters F, Rödel C, Rutten H, van de Velde C, Aristei C. The 2017 Assisi Think Tank Meeting on rectal cancer: A positioning paper. Radiother Oncol 2019; epub ahead of print.

Fokas E, Glynne-Jones R, Appelt A, Beets-Tan R, Beets G, Haustermans K, Marijnen C, Minsky BD, Ludmir E, Quirke P, Sebag-Montefiore D, Garcia-Aguilar J, Gambacorta MA, Valentini V, Buyse M, Rödel C. Outcome measures in multimodal rectal cancer trials. Lancet Oncol 2020 ;21:e252-e264.

Martin D, Balermpas P, Gollrad J, Weiß C, Valentini C, Stuschke M, Schäfer H, Henckenberens C, Debus J, Krug D, Kuhnt T, Brunner T, Bostel T, Engenhart-Cabillic R, Nestle U, Combs S, Belka C, Hautmann M, Hildebrandt G, Gani C, Polat B, Rödel C, Fokas E. RADIANCE - Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trial. Clin Transl Radiat Oncol 2020;23:43-49.

Attenberger U, Rödel C, Ghadimi M, Piso P, Arnold D, Folprecht G, Geissler M, Hegewisch-Becker S, Heinemann V, Kasper S, Modest D, Reinacher-Schick A, Seufferlein T, Stein A, Stintzing S, Hofheinz RD. Prerequisites of magnetic resonance imaging for treatment planning in locally advanced rectal cancer - Interdisciplinary recommendations. Z Gastroenterol 2020;58(6):577-582.

Röder F, Meldolesi E, Gerum S, Valentini V, Rödel C. Recent advances in (chemo-)radiation therapy for rectal cancer: a comprehensive review. Radiat Oncol 2020;15:262.

Czito B, Rödel C. Emerging Treatment Paradigms in Localized Rectal Cancer. Pract Radiat Oncol 2021;11:26-29.

Güllülü Ö, Hehlgans S, Rödel C, Fokas E, Rödel F. Tumor suppressor protein p53 and inhibitor of apoptosis proteins in colorectal cancer – a promising signalling network for therapeutic interventions. Cancers 2021;13:624.

Siegel R, Werner RN, Koswig S, Gaskins M, Rödel C, Aigner F. Anal Cancer-Diagnosis, Treatment and Follow-up. Dtsch Arztebl Int 2021;118:217-24.

Werner RN, Gaskins M, Avila Valle G, Budach V, Koswig S, Mosthaf FA, Raab HR, Rödel C, Nast A, Siegel R, Aigner F State of the art treatment for stage I to III anal squamous cell carcinoma: a systematic review and meta-analysis. Radiother Oncol 2021:157:188-196.

Aigner F, Werner RN, Koswig S, Gaskins M, Rödel C, Kahlke V, Raab HR, Siegel R; die Leitliniengruppe Analkarzinom. Summary and comments on the S3 guideline on anal cancer: diagnostics, treatment and aftercare of anal canal and margin cancers. Chirurg 2021:92:244-247.

Lapa C, Nestle U, Albert NL, Baues C, Beer A, Buck A, Budach V, Bütof R, Combs SE, Derlin T, Eiber M, Fendler WP, Furth C, Gani C, Gkika E, Grosu AL, Henkenberens C, Ilhan H, Löck S, Marnitz-Schulze S, Miederer M, Mix M, Nicolay NH, Niyazi M, Pöttgen C, Rödel CM, Schatka I, Schwarzenboeck SM, Todica AS, Weber W, Wegen S, Wiegel T, Zamboglou C, Zips D, Zöphel K, Zschaeck S, Thorwarth D, Troost EGC. Value of PET imaging for radiation therapy. Strahlenther Onkol 2021;197:1-23.

Fokas E, Appelt A, Glynne-Jones R, Beets G, Perez R, Garcia-Aguilar J, Rullier E, Smith JJ, Marijnen C, Peters FP, van der Valk M, Beets-Tan R, Myint AS, Gerard JP, Bach SP, Ghadimi M, Hofheinz RD, Bujko K, Gani C, Haustermans K, Minsky BD, Ludmir E, West NP, Gambacorta MA, Valentini V, Buyse M, Renehan AG, Gilbert A, Sebag-Montefiore DS, Rödel C. International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer. Nat Rev Clin Oncol 2021;12:805-816.

Fleischmann M, Glatzer M, Rödel C, Tselis N. Radioimmunotherapy: future prospects from the perspective of brachytherapy. J Contemp Brachytherapy 2021;13:458-467.

Fleischmann M, Chatzikonstantinou G, Fokas E, Wichmann J, Christiansen H, Strebhardt K, Rödel C, Tselis N, Rödel F. Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer. Cancers 2021;13:5748.

Dapper H, Belka C, Bock F, Budach V, Budach W, Christiansen H, Debus J, Distel L, Dunst J, Eckert F, Eich H, Eicheler W, Engenhart-Cabillic R, Fietkau R, Fleischmann DF, Frerker B, Giordano FA, Grosu AL, Herfarth K, Hildebrandt G, Kaul D, Kölbl O, Krause M, Krug D, Martin D, Matuschek C, Medenwald D, Nicolay NH, Niewald M, Oertel M, Petersen C, Pohl F, Raabe A, Rödel C, Rübe C, Schmalz C, Schmeel LC, Steinmann D, Stüben G, Thamm R, Vordermark D, Vorwerk H, Wiegel T, Zips D, Combs SE. Integration of radiation oncology teaching in medical studies by German medical faculties due to the new licensing regulations : An overview and recommendations of the consortium academic radiation oncology of the German Society for Radiation Oncology (DEGRO). Strahlenther Onkol 2022:198:1-11.

Corrigan KL, Kry S, Howell RM, Kouzy R, Jaoude JA, Patel RR, Jhingran A, Taniguchi C, Koong AC, McAleer MF, Nitsch P, Rödel C, Fokas E, Minsky BD, Das P, Fuller CD, Ludmir EB. The Radiotherapy Quality Assurance Gap Among Phase III Cancer Clinical Trials. Radiother Oncol 2021;166:51-57.

Fleischmann M, Diefenhardt M, Fokas E, Rödel C, Rödel F. Molekulare Prädiktoren des Tumoransprechens auf eine Radiochemotherapie des Rektumkarzinoms. Der Onkologe 2021; published online.

Conradi LC, Rödel C, Ghadimi M. Rectal Cancer: Open Questions in 2022 Current Standards of Clinical Practice and Ongoing Trials. Digestion 2022;103:175-182.

Fleischmann M, Nicolas AM, Rödel F, Ghadimi M, Hofheinz RD, Greten FR, Rödel C, Fokas E. ACO/ARO/AIO-21 - Capecitabine-based Chemoradiotherapy in Combination with the IL-1 Receptor Antagonist Anakinra for Rectal Cancer Patients: A Phase I Trial of the German Rectal Cancer Study Group. Clin Transl Radiat Oncol 2022;34:99-106.

George R, Hehlgans S, Fleischmann M, Rödel C, Fokas E, Rödel F. Advances in nanotechnology-based platforms for survivin-targeted drug discovery. Expert Opin Drug Discov 2022;17:733-754 .

Ghadimi M, Rödel C, Hofheinz R, Flebbe H, Grade M. The Multimodal Treatment of Rectal Cancer. Dtsch Arztebl Int 2022;119:570-580.

Schmid SC, Lewerich J, Retz M, Rödel C. Surgery only" is not enough: potential of multimodal therapy in urothelial bladder carcinoma. Urologie 2022;61:1332-1340.

Fokas E, Glynne-Jones R, Fleischmann M, Piso P, Tselis N, Ghadimi M, Hofheinz RD, Rödel C. Radiotherapy dose escalation using endorectal brachytherapy in elderly and frail patients with rectal cancer unsuitable for surgery: Lessons from studies in fit patients and future perspectives. Cancer Treat Rev. 2022;112:102490.

Rödel C. Amplifikation von 11q13-DNA-Markern bei Plattenepithel- lkarzinomen im Kopf-Hals-Bereich: Korrelation mit dem klinischen Verlauf. Kommentar zu: Muller D, Millon R, Velten M, et al. Amplification of 11q13 DNA markers in head and neck squamous cell carcinomas: correlation with clinical outcome. Eur J Cancer 1997;33:2203-10. Strahlenther Onkol 1998;174:642-3.

Rödel C. Wirksamkeit und Toxizitätsspektrum der kontinuierlichen 5-Fluorouracil-Infusion im Vergleich zur Bolusgabe bei fortgeschrittenen kolorektalen Tumoren. Strahlenther Onkol 1999;175:294-295.

Rödel C, Sauer R. Addendum zum Beitrag: Adjuvante und neoadjuvante Therapie des Rektumkarzinoms. Strahlenther Onkol 1999;175:133.

Rödel C. Bedeutung des Intervalls zwischen präoperativer Bestrahlung und Operation bei der Behandlung des Rektumkarzinoms. Strahlenther Onkol 2000;176:153-154.

Fietkau R, Rödel C. Die postoperative Radiochemotherapie des Rektum- karzinoms verringert die Häufigkeit lokoregionärer Rezidive, verbessert aber nicht die Prognose der Patienten – Ergebnisse einer randomisierten Studie der NSABP-R-02. Strahlenther Onkol 2000;176:381-382.

Rödel C, Sauer R. Multimodale Therapie des Rektumkarzinoms beibehalten. Dt. Ärzteblatt 2000;97:A 2542-2543.

Rödel C. Multimodale Therapiekonzepte: Rektumkarzinom. Z Gastroenterol 2003;41:Suppl 1:14-15.

Rödel C, Meyer M. In reply to Goel S: Alternatives to Cystectomy in muscle-invasive bladder cancer. J Clin Oncol 2003;21:3003-3004.

Rödel F, Rödel C. Der Rezeptor für den epidermalen Wachstumsfaktor ist ein Prädiktor für die Tumorantwort nach präoperativer Radiotherapie bei Patienten mit lokal fortgeschrittenem Rektumkarzinom. Strahlenther Onkol 2003;8:578-579.

Rödel C. Kongressbericht Rothenburg o.d.T., 9. Interdiziplinäres Symposium Interdiziplinäre Onkologie – Rothenburg 2003. Forum DKG 2003;3:12

Weiss C, Rödel C. Die neoadjuvante Chemotherapie vor Zystektomie verbessert die Prognose beim Harnblasenkarzinom: Konsequenzen für den Radiotherapeuten? Strahlenther Onkol 2004;180:246-247.

Rödel C. Organerhalt beim invasiven Harnblasenkarzinom durch Radio- chemotherapie. MedReview 2004;4:19-20.

Rödel C, Sauer R. Sphinktererhaltende Operation nach Kurzzeit-Radio- therapie und konventionell fraktionierter Radiochemotherapie beim Rektumkarzinom: Geht die Kontroverse weiter? Strahlenther Onkol, 2004;180:396-398.

Rödel C. Rectal cancer: What evidence from the use of preoperative radiotherapy associated with new drugs? ESTRO Teaching Course: Interdisciplinary management of gastrointestinal cancer. 2004;123-142.

Sauer R, Rödel C. Chemoradiotherapy for rectal cancer. Reply. N Engl J Med 2005;352:510-511.

Rödel C, Sauer R. In reply to Machiels J.-P. et al: What is best to predictdisease-free survival after preoperative radiochemotherapy for rectal cancer patients? J Clin Oncol 2006;24:1319.

Sauer R, Rödel C. Autorreferat: Präoperative versus postoperative Radiochemotherapie beim lokal fortgeschrittenen Rektumkarzinom. Internistische Praxis 2006;1:25-28.

Rödel C. Neoadjuvante Chemotherapie mit Capecitabin und Oxaliplatin vor simultaner Radiochemotherapie und totaler Mesorektumresektion beim Rektumkarzinom. Strahlenther Onkol 2006;182:421-3.

Priske A, Rödel C. Vergleichende Phase-III-Studie beim „primär inoperablen“ Rektumkarzinom: Alleinige Präoperative Radiotherapie oder kombinierte Radiochemotherapie. Strahlenther Onkol 2009;185:339-40.

Rödel C. Neoadjuvante Radiochemotherapie mit 5-FU plus Oxaliplatin beim lokal fortgeschrittenen Rektumkarzinom. Erste Ergebnisse aus Phase-III-Studien. Strahlenther Onkol 2012;188:446-7.

Rödel C, Klautke G. Local control in T3 rectal cancer : Short-course radiotherapy versus chemoradiation. Strahlenther Onkol 2013;189:166-7.

Minsky BD, Rödel C. Identifying the most predictive post-chemoradiation TRG system for rectal cancer. J Natl Cancer Inst 2014;106(10).

Rödel C, Weiss C. Organ-sparing multimodality treatment for muscle-invasie bladder cancer: Can we continue to ignore the evidence? J Clin Oncol 2014; 32:3787-8.

Hofheinz RD, Rödel C, Burkholder I, Kienle P. Adjuvant chemotherapy for rectal cancer. Lancet Oncol 2015;16:e154-5.

Trojan J, Bechstein WO, Vogl T, Rödel C, Woeste G. Diagnostik und Therapie des kolorektalen Karzinoms – Fortschritte durch Interdiziplinarität. Hessisches Ärzteblatt 2015;6:330-4.

Rödel C, Fokas E. Inclusion of oxaliplatin in the multimodal treatment of locally advanced rectal cancer. Strahlenther Onkol 2017;193:168-70

Martin D, Rödel C, Fokas E. How long should we wait upon completion of chemoradiotherapy before assessment of tumor response in anal cancer? Strahlenther Onkol 2017;193:593-94.

Fokas E, Rödel C. Optimal fractionation regimen, and time between radiotherapy and operation in rectal cancer: The multicenter, randomized Stockholm III trial. Strahlenther Onkol 2017;193

Martin D, Rödel C, Fokas E. Chemoradiotherapy for anal cancer: are we as good as we think? Strahlenther Onkol 2019;195:369-373.

Marijnen CAM, Peters FP, Rödel C, Bujko K, Haustermans K, Fokas E, Glynne-Jones R, Valentini V, Spindler KG, Guren MG, Maignon P, Calvo FA, Pares O, Glimelius B, Sebag-Montefiore D. International expert consensus statement regarding radiotherapy treatment options for rectal cancer during the COVID 19 pandemic. Radiother Oncol 2020:148:213-215.

Fokas E, Rödel C. Preoperative treatment of rectal cancer-Critical comments on the US-American PROSPECT trial. Strahlenther Onkol 2023;199(8):781-783.

Fleischmann M, Rödel C. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer. Strahlenther Onkol 2023; epub ahead of print.

Fokas E, Rödel C, Smith JJ, Garcia-Aguilar J, Buyse M, Glynne-Jones R. Disease-free survival as the endpoint in multimodal rectal cancer trials: have we got this right? Lancet Gastroenterol Hepatol 2023; epub ahead of print.